WO2006055695A1 - Device and method for lung treatment - Google Patents

Device and method for lung treatment Download PDF

Info

Publication number
WO2006055695A1
WO2006055695A1 PCT/US2005/041651 US2005041651W WO2006055695A1 WO 2006055695 A1 WO2006055695 A1 WO 2006055695A1 US 2005041651 W US2005041651 W US 2005041651W WO 2006055695 A1 WO2006055695 A1 WO 2006055695A1
Authority
WO
WIPO (PCT)
Prior art keywords
vapor
tissue
condensable vapor
lung
targeted region
Prior art date
Application number
PCT/US2005/041651
Other languages
French (fr)
Inventor
Robert L. Barry
Brian Cran
Dean Corcoran
Sheldon K. Lee
Original Assignee
Barry Robert L
Brian Cran
Dean Corcoran
Lee Sheldon K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35929697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006055695(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Barry Robert L, Brian Cran, Dean Corcoran, Lee Sheldon K filed Critical Barry Robert L
Priority to EP05823129A priority Critical patent/EP1833397A1/en
Priority to CN2005800466068A priority patent/CN101115448B/en
Priority to MX2007005937A priority patent/MX2007005937A/en
Priority to CA2587909A priority patent/CA2587909C/en
Priority to BRPI0518437-1A priority patent/BRPI0518437A2/en
Priority to JP2007543222A priority patent/JP5020824B2/en
Publication of WO2006055695A1 publication Critical patent/WO2006055695A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
    • A61B1/267—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
    • A61B1/2676—Bronchoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/08—Detecting organic movements or changes, e.g. tumours, cysts, swellings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/12—Devices for heating or cooling internal body cavities
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/005—Devices for introducing or retaining media, e.g. remedies, in cavities of the body for contrast media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N7/02—Localised ultrasound hyperthermia
    • A61N7/022—Localised ultrasound hyperthermia intracavitary
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00017—Electrical control of surgical instruments
    • A61B2017/00022—Sensing or detecting at the treatment site
    • A61B2017/00106—Sensing or detecting at the treatment site ultrasonic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053—Mechanical features of the instrument of device
    • A61B2018/00273—Anchoring means for temporary attachment of a device to tissue
    • A61B2018/00279—Anchoring means for temporary attachment of a device to tissue deployable
    • A61B2018/00285—Balloons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00541—Lung or bronchi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00994—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body combining two or more different kinds of non-mechanical energy or combining one or more non-mechanical energies with ultrasound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B2018/044—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating the surgical action being effected by a circulating hot fluid
    • A61B2018/048—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating the surgical action being effected by a circulating hot fluid in gaseous form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2218/00—Details of surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2218/001—Details of surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body having means for irrigation and/or aspiration of substances to and/or from the surgical site
    • A61B2218/002—Irrigation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2218/00—Details of surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2218/001—Details of surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body having means for irrigation and/or aspiration of substances to and/or from the surgical site
    • A61B2218/007—Aspiration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1025—Respiratory system
    • A61M2210/1039—Lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N2007/0004—Applications of ultrasound therapy

Definitions

  • the present invention relates to the treatment of a patient's lung, for example, the treatment of chronic obstructive pulmonary diseases (COPD).
  • COPD chronic obstructive pulmonary diseases
  • this invention relates to systems, devices and methods for affecting lung volume reduction for the treatment of COPD, such as emphysema.
  • COPD chronic obstructive pulmonary disease
  • emphysema chronic obstructive pulmonary disease
  • COPD is generally characterized by airflow obstruction, which in particular limits the patient's air flow during expiration.
  • Patients with chronic bronchitis have chronic cough with sputum production leading to obstructed expiration.
  • destruction of lung parenchyma can lead to loss of elastic recoil, reduced tethering of the airways, obstruction to expiration, and cough.
  • Lung function as well as quality of life in patients suffering with a COPD can be improved by reducing a patient's effective lung volume.
  • One way to reduce effective lung volume is by surgically removing diseased portions of the lungs, both to promote expansion of the non-diseased regions, realign a patient's diagraph and to redirect inhaled air from diseased portions of lungs into healthier, better functioning lung regions.
  • Surgery often results in effective volume reduction of about 15-30%, which may not be sufficient to cause an appreciable improvement in lung function.
  • conventional lung reduction surgery is traumatic, even when thorascopic procedures are employed.
  • This invention relates to the treatment of a patient's lung, for example, the treatment of chronic obstructive pulmonary disease (COPD) and other conditions that can be treated by decreasing a patient's effective lung volume.
  • COPD chronic obstructive pulmonary disease
  • methods and devices of the invention relate to treatment for affecting lung volume reduction by delivering a thermal damaging agent to a targeted region of a patient's lung so that the region is essentially non-functional.
  • a method of treating a patient's lung includes delivering a thermal damaging agent to a targeted region of the patient's lung to raise the temperature of the tissue in the region sufficiently high to the extent that blood flow and air flow within the targeted region are terminated.
  • the thermal damaging agent damages at least one of the group consisting of tissue defining at least in part an air sac of the targeted region, tissue of terminal bronchioles in the targeted region and collateral passageways in the targeted region.
  • the method can also include occluding an airway of the lung through which the thermal damaging agent is delivered at a point proximal to where the thermal damaging agent enters the target region so as to isolate the region and prevent excursions of the thermal damaging agent to areas outside the target region.
  • One preferred method of treating a patient's lungs includes delivering a condensable vapor at a temperature above body temperature at atmospheric pressures to lung tissue of the target region, particularly the tissue defining at least in part an air sac within the patient's lung.
  • the device for delivering a thermal damaging agent includes an elongate shaft having a proximal portion, a distal portion, and a thermal damaging agent delivering lumen extending within at least a distal portion of the shaft.
  • the device has at least one discharge port in the distal portion of the elongate shaft in fluid communication with the thermal damaging agent delivering inner lumen.
  • a thermal damaging agent generator is in fluid communication with the thermal damaging agent delivery lumen in the elongate shaft and is configured for generating a thermal damaging agent at a temperature above 40 0 C to the tissue at the targeted region to render the region essentially non ⁇ functional.
  • the device also includes an occluding member disposed on a distal portion of the shaft to occlude the airway passage proximal to the delivery location of the thermal damaging agent.
  • the device includes an elongate shaft having a proximal portion, a distal portion, and a vapor delivering inner lumen extending within at least the distal portion of the shaft.
  • the device has at least one discharge port in the distal portion of the elongate shaft in fluid communication with the vapor delivering inner lumen configured to deliver condensable vapor to the target region.
  • a condensable vapor generator is provided in fluid communication with the vapor delivering lumen of the elongate shaft for generating a condensable vapor at a temperature above 40 0 C to thermally damage tissue at the targeted region sufficiently to terminate blood flow and air flow to the targeted region.
  • the device also includes an occluding member disposed on a distal portion of the shaft.
  • the delivered condensable vapor is generally about 40° to 80° C, and preferably is about 50° to about 60° C.
  • the condensable vapor is delivered to the targeted region for a period of about 5 seconds to about 10 minutes, preferably about 5 seconds to about 10 seconds.
  • Suitable liquids for forming the condensable vapor includes water based fluids and perfluorocarbon
  • Figure 1A illustrates a method for treating a patient's lung embodying features of the invention.
  • Figure 1 B is an enlarged view of an air sac and alveoli within the patient's lung shown in Figure 1A...
  • Figure 2 is a longitudinal cross sectional view of the device shown in Figure 2.
  • Figures 3A is a transverse cross sectional view of the device shown in Figure 2, taken along lines 3A-3A.
  • Figure 3B is a transverse cross sectional view of the device shown in
  • Figure 4 is an elevational view, partially in perspective, of a system embodying features of the invention.
  • Figure 5A is an elevational view of a vapor generator connected to the device shown in Figure 2.
  • Figure 5B is an elevational view of a vapor generator connected to the device shown in Figure 2 which has a cartridge for storing vaporizable fluid.
  • Figure 5C is an elevational view of a vapor generator connected to the device shown in Figure 2 which is connected to a hand held operator or pistol grip handle.
  • Figure 1 illustrates a method for treating a patient's lung 10 embodying features of the invention that includes delivering a condensable vapor 12 to tissue defining an air sac or alveoli 14 within a patient's lung 10 at a temperature above body temperature, preferably about 40 0 C to about 80 0 C, preferably about 50°C to about 60°C at atmospheric pressures, so as to damage the tissue of the air sac or alveoli 14, the tissue of terminal bronchioles 16 and tissue of collateral passageways 18.
  • tissue damage renders the treated region non-functional in that the blood flow and air flow in the treated region is terminated.
  • the treated region will no long inflate.
  • the method includes delivering the condensable vapor through an airway 20 of the lung to the targeted lung region.
  • the airway 20 is a bronchial passageway such as segmental bronchi, and most preferably a sub segmental bronchi 20.
  • the condensable vapor 12 serves to rapidly heat the targeted lung region as the vapor 12 is delivered and induces tissue collapse, shrinkage, neointima hyperplasia, necrosis and fibrosis (collectively referred to herein as "bioeffects") of the targeted lung region. Such bioeffects render the target lung region non ⁇ functioning.
  • the method may also include applying a vacuum to the targeted region after delivery of the condensable vapor to further supplement tissue contraction and collapse caused by introduction of the condensable vapor 12.
  • the vacuum generated in the targeted region is about 1 to about 50 mm Hg, preferably about 10 to about 30 mm Hg to effectively collapse the targeted region.
  • the vacuum may also facilitate aspiration of any residual vapor or liquid.
  • the vapor is applied into the targeted region through an airway for anywhere from 5 seconds to 10 minutes or longer.
  • the condensable vapor is delivered for a short period of time, about 5 seconds to 10 seconds.
  • tissue heating and the resulting damage is rapid using energetic vapor, short vapor application times are preferred.
  • less vapor may be used to cause gradual tissue bioeffects or to treat larger regions or volumes of tissue.
  • Separate procedures may be utilized for separate regions to be treated.
  • the condensable vapor 12 maybe generated from a liquid, for example, sterile water or other fluids such as perfluorocarbons, having relatively high liquid- gas phase-change temperatures, i.e. boiling points, preferably temperatures well above body temperature.
  • the condensable vapor 12 is at a temperature sufficient to increase the temperature of the surrounding lung parenchyma to cause damage, for example, above at least 40 0 C.
  • the condensable vapor 12 additionally includes a detectable substance, such as a dye, preferably a biocompatible dye, to detect movement of the condensable vapor 12 and the affected lung regions.
  • a detectable substance such as a dye, preferably a biocompatible dye
  • diagnostic ultrasound, endoscopic and other conventional visualization techniques are used to monitor the vapor treatment and resulting tissue effects during and after treatment.
  • the condensable vapor 12 is delivered with microparticulates. Suitable microparticulates include talc, calcium carbonate, antibiotics such as tetracycline and other penicillin derivates, or other particulate substances which induce fibrosis or cause necrosis of the lung tissue.
  • the condensable vapor 12 includes a treatment agent such as an anesthetic or painkillers to alleviate patient discomfort and pain during the treatment.
  • a painkiller such as lidocane in powder or liquid form, preferably is used or mixed with a condensable vapor 12.
  • pain killers may be delivered to the entire lung, or just to the targeted lung region. Patient preparation with pain medication before, during, and after the procedure is preferred in order to allow treatment using the present invention without the need for general anesthesia.
  • helium or carbon dioxide is delivered in addition to the vapor 12 to lower the temperature of the vapor 12.
  • a method of the invention includes occluding the airway of a lung proximal to the area where the condensable vapor 12 is delivered.
  • the adjacent airways are filled with a fluid, such as saline.
  • Airways leading to untargeted lung regions may be obstructed to prevent vapor flow therein.
  • high intensity focused ultrasound (HIFU) energy is delivered to damage lung tissue such as the tissue of an air sac or alveoli in the lung.
  • suitable ultrasound transducers that are capable of delivering high intensity focused ultrasound (HIFU), generally between about 100-10,000 W/cm 2 at a focal spot.
  • the HIFU energy is delivered in amounts sufficient to cause contraction of lung tissue. Because HIFU can be tightly controlled, the ultrasound energy can be specifically targeted to the epithelium, smooth muscle layer, or collagen layer. Delivery of the HIFU energy can also serve to initiate a healing response (including neointima hyperplasia) which further serves to occlude the passageway.
  • the method can include a wave guide to direct the HIFU sound waves to the intended treatment site. Additionally a vacuum may be applied prior the HIFU to draw down the airway or air sacs. Alternatively the vacuum may be applied after delivery of the HIFU energy as in the previously discussed embodiment to further supplement tissue contraction and collapse of the terminal bronchioles, air sacs and collateral passageways caused by introduction of the ultrasound energy.
  • an ultrasound absorptive material such as a liquid or gel
  • the absorptive material is heated by the HIFU energy in order to thermally damage the surrounding tissue, resulting in contraction of the airway and or neointima hyperplasia, which will occlude the airway and or damage the air sacs of the lung.
  • RF energy can be delivered to a desired location within a patient's lung to damage lung tissue but this usually requires a conductive fluid in contact with the lung tissue for effective ablation.
  • Figure 2 depicts a system 22 embodying features of the invention including an elongate shaft 24 having a distal portion 26 and a proximal portion 28.
  • Figure 2 is a longitudinal cross sectional view of the elongate shaft 24 and Figures 3A and 3B show transverse cross sectional views of the elongate shaft along the lines 3A-3A and lines 3B-3B shown in Figure 2.
  • the elongated shaft 24 has at least one discharge port 30 in the distal portion 26 of the shaft configured to discharge condensable vapor 12 and a vapor delivering lumen 32 disposed within the elongate shaft 24 in fluid communication with the discharge port 30.
  • a vapor generator 34 is connected to the lumen 32 of the elongate shaft.
  • the elongate shaft 24 also contains a vacuum lumen 36 which is configured to be connected to a vacuum source for application of a vacuum through vacuum port 38 in the distal portion 26 of the elongate shaft.
  • the elongated shaft 24 is also provided with an inflation lumen 40 which leads to the inflation port 42. Port 42 opens to the interior 44 of the inflatable balloon 46 which is secured to the distal portion 26 of the shaft.
  • the inflation device 48 may be a conventional syringe.
  • the occluding member 46 is preferably expandable, compliant, and is configured to prevent vapor flow proximal to the location of the member. Suitable balloon materials include silicone or latex.
  • the exterior of the working surface of the inflatable balloon 46 is preferably provided with a knurled or roughened surface to better engage the airway walls and prevent recoil when the condensable vapor is delivered to the target location.
  • a venting system may be included with the device to ensure that high pressure does not exceed suitable limits.
  • the venting system includes a venting lumen 50 in the shaft 24 which is in fluid communication with the port 52 in the distal end of the shaft 24.
  • the venting mechanism can be a pressure actuated relief valve 54.
  • the device 22 also includes a temperature sensor 56, for example a thermocouple, located on the distal portion 26 of the elongate shaft 24 to monitor the surrounding temperature. When the temperature is too high, the lung region is brought back to normal temperatures with a lavage or washout procedure to facilitate removal of residual vapor.
  • a temperature sensor 56 for example a thermocouple
  • the device 22 preferably includes a pressure sensor 58 on the distal portion 26 of the elongate shaft 24 to detect pressure within the targeted lung region.
  • the pressure sensor 58 communicates with a pressure gauge 60 on the proximal portion 28 of the elongate shaft 24.
  • the pressure sensing system may be tied in with the venting system to ensure that preset pressure limits are not exceeded during vapor delivery. Over inflation of the target region could lead to air leaks and tears in the lung pleura.
  • a suitable flow meter (not shown) may be included to monitor vapor flow to the targeted region of the patient's lung.
  • the elongate shaft 24 is configured to be delivered through the working channel (not shown) of an endoscope 62, preferably a bronchoscope.
  • the working channel of the endoscope 62 is preferably between about 1.5 mm and 3.5 mm.
  • the endoscope 62 is connected to an endoscope controller 64 and an endoscope monitor 66.
  • the distal portion 26 of the elongate shaft 24 is flexible to facilitate advancement of the elongate shaft in the working channel of the endoscope 56, while the proximal portion 28 is sufficiently rigid for good pushability of the shaft through and out of a distal opening of the endoscope.
  • the distal portion 26 of the shaft 24 is about 1-6 French, the occluding balloon when inflated is larger than the working channel of the endoscope and is typically about 8 French.
  • a suitable endoscope is the Olympus LF-TP bronchoscope.
  • airways adjacent the delivery airway can be obstructed, for example, with a fluid such as saline.
  • the fluid in the adjacent airways prevents condensable vapor 12 from entering into other lung regions which are not targeted for treatment and prevents damage of the adjacent regions.
  • the vapor generator 34 is external to the elongate shaft 24 and stores the liquid supply.
  • the vapor generator 34 has an outer housing 72 which houses internal structures including a liquid chamber 74 and an inner vapor conduit 76. Liquid may be loaded directly into the liquid chamber.
  • the inner vapor conduit 76 extends from the liquid chamber 74 of the vapor generator 34 to the proximal portion 26 of the first lumen 32 and receives the condensable vapor 12 from the liquid chamber 74 a via an inlet port 78.
  • the vapor generator 34 couples to the elongate shaft 24 via a luer fitting or similar mechanism.
  • the liquid chamber 74 has heating elements such as resistive heating elements, or a RF heater or the like for vaporizing liquid inside the liquid chamber to a condensable vapor.
  • the vapor travels from the liquid chamber 74 through the inner vapor conduit 76 and exits into the proximal portion of the vapor lumen 32 of the elongate shaft 24 of the device.
  • the vapor generator includes a cartridge compartment 80 which receives a cartridge 82 in fluid communication with the lumen 32 and containing a predetermined amount of liquid for vaporizing.
  • the cartridge 82 is configured to preferably snap-fit into the compartment 80.
  • the vapor generator 34 When the vapor generator 34 is activated the fluid in the cartridge 82 is heated to a vapor. The condensable vapor 12 is then delivered to the proximal end of the first lumen 32. A predetermined volume or amount of vapor pressure to be delivered to a patient's lung 10 can be determined or calculated based on diagnostic evaluations or parameters of the patient before the treatment procedure, such as forced expiratory volume (FEV) or other lung function and capacity indicators.
  • the vapor generator 34 as shown in Figure 5C has an inner vapor conduit 76 which extends into a generator tube 84.
  • the generator tube 84 connects to a pistol grip handle 86 which is configured to couple to the proximal portion 26 of the elongate shaft.
  • the pistol grip handle 86 can be used to activate heating of the vapor 12 within the liquid chamber 74 of the vapor generator 34.
  • the condensable vapor travels from the vapor generator 34 to the pistol grip 86 and into the elongate shaft 24.
  • the vapor generator 34 can be disposed within the elongate shaft 24.
  • the heating elements for example an RF electrode or emitter such as a helical coil, may be embedded within the wall of the shaft, surrounding the lumen 32.
  • the heater may be used as an alternative to the vapor generator 34 or to augment or further control the temperature of the vapor leaving the discharge port 30 from lumen 32.
  • the elongate shaft 24 of the device 22 is heat insulated to avoid overheating of the elongate shaft 24 inside the endoscope 62.
  • the elongate shaft 24 contains a liquid lumen (not shown) and a cooling fluid is delivered within this lumen to prevent overheating.
  • the condensable vapor 12 is a substance which is capable of rapidly heating a region of the lung to render the target region non-functioning where there is little or no blood flow or air flow within the region.
  • Suitable condensable vapors 12 are selected from the group consisting of condensable vapors from aqueous based fluids, for example, sterile water, saline, contrast fluid, and other fluids such as perfluorocarbons, liquid antibiotics, and other liquids having high liquid-gas phase- change temperatures, i.e. boiling point, preferably above body temperature.
  • the condensable vapor 12 is at a temperature sufficient to increase the temperature of the tissue at the target site to cause tissue damage.
  • the condensable vapor 12 includes a detectable substance, such as a dye or a biocompatible dye, to allow the physician to visually track progress of treatment and which lung regions have been treated.
  • a detectable substance such as a dye or a biocompatible dye
  • diagnostic ultrasound, endoscopic and other conventional visualization techniques are used to monitor the condensable vapor treatment and resulting tissue effects during and after treatment.
  • the condensable vapor 12 comprises a treatment agent such as a pain-numbing substance or painkillers to alleviate patient discomfort and pain during the treatment.
  • a painkiller such as lidocane in aqueous powder or liquid form, preferably is used or mixed with a condensable vapor 12.
  • pain killers are delivered to the entire lung, or the targeted lung region.
  • patient preparation with pain medication before, during, and after the procedure is preferred in order to allow treatment using the present invention without the need for general anesthesia.
  • the device can include a drug delivery lumen in fluid communication with a drug delivery port in the distal portion of the elongate shaft. Painkillers or other drugs can be delivered to the desired area through the optional drug delivery lumen.
  • the elongate shaft 24 of device 22 has a helium or carbon dioxide delivery lumen (not shown) for delivering helium or carbon dioxide in addition to the vapor 12 to lower the temperature of the condensable vapor 12.
  • a helium or carbon dioxide delivery lumen (not shown) for delivering helium or carbon dioxide in addition to the vapor 12 to lower the temperature of the condensable vapor 12.

Abstract

This invention relates to the treatment of a patient's lung, for example, a lung exhibiting chronic obstructive pulmonary disease (COPD) and in particular to methods and devices for affecting lung volume reduction, preferably for achieving acute or immediate lung volume reduction following treatment. The lung volume reduction is effected by delivering a condensable vapor at a temperature above body temperature to the desired regions of the patient's lung to damage tissue therein. Blood flow and air flow to the damaged tissue region is essentially terminated, rendering the target region non-functional. Alternative energy sources may be used to effect the thermal damage to the lung tissue.

Description

DEVICE AND METHOD FOR LUNG TREATMENT
FIELD OF THE INVENTION
[0001] The present invention relates to the treatment of a patient's lung, for example, the treatment of chronic obstructive pulmonary diseases (COPD). In particular this invention relates to systems, devices and methods for affecting lung volume reduction for the treatment of COPD, such as emphysema.
BACKGROUND OF THE INVENTION
[0002] Chronic obstructive pulmonary disease (COPD) includes chronic bronchitis and emphysema. COPD is generally characterized by airflow obstruction, which in particular limits the patient's air flow during expiration. Patients with chronic bronchitis have chronic cough with sputum production leading to obstructed expiration. In patients with emphysema, destruction of lung parenchyma can lead to loss of elastic recoil, reduced tethering of the airways, obstruction to expiration, and cough.
[0003] Lung function as well as quality of life in patients suffering with a COPD can be improved by reducing a patient's effective lung volume. One way to reduce effective lung volume is by surgically removing diseased portions of the lungs, both to promote expansion of the non-diseased regions, realign a patient's diagraph and to redirect inhaled air from diseased portions of lungs into healthier, better functioning lung regions. Surgery often results in effective volume reduction of about 15-30%, which may not be sufficient to cause an appreciable improvement in lung function. Also, conventional lung reduction surgery is traumatic, even when thorascopic procedures are employed.
[0004] Recently, bronchoscopic approaches for reducing effective lung volume have been proposed. See for example, U.S. Patents 6,592,594, 6,679,264, 6,398,775 and 6,610,043; and U.S. Patent Publications 2003/0181922, 2004/0055606, and 2004/0047855. One challenge to achieving effective lung reduction, particularly in emphysematous lungs, is collateral ventilation or collateral pathways.
[0005] According, there is a need for devices, methods and systems for reducing effective lung volume without surgery, and also for reducing lung volume in the presence of collateral pathways. The present invention is directed to meeting these, as well as other, needs.
SUMMARY OF THE INVENTION
[0006] This invention relates to the treatment of a patient's lung, for example, the treatment of chronic obstructive pulmonary disease (COPD) and other conditions that can be treated by decreasing a patient's effective lung volume. In particular methods and devices of the invention relate to treatment for affecting lung volume reduction by delivering a thermal damaging agent to a targeted region of a patient's lung so that the region is essentially non-functional.
[0007] A method of treating a patient's lung includes delivering a thermal damaging agent to a targeted region of the patient's lung to raise the temperature of the tissue in the region sufficiently high to the extent that blood flow and air flow within the targeted region are terminated. Preferably the thermal damaging agent damages at least one of the group consisting of tissue defining at least in part an air sac of the targeted region, tissue of terminal bronchioles in the targeted region and collateral passageways in the targeted region. The method can also include occluding an airway of the lung through which the thermal damaging agent is delivered at a point proximal to where the thermal damaging agent enters the target region so as to isolate the region and prevent excursions of the thermal damaging agent to areas outside the target region.
[0008] One preferred method of treating a patient's lungs includes delivering a condensable vapor at a temperature above body temperature at atmospheric pressures to lung tissue of the target region, particularly the tissue defining at least in part an air sac within the patient's lung.
[0009] A device for delivering a thermal damaging agent to a targeted region of the patient's lung to raise the temperature of the lung tissue in the targeted region sufficiently high to render the targeted region essentially non-functional wherein neither blood flow or air flow occurs within the region. The device for delivering a thermal damaging agent includes an elongate shaft having a proximal portion, a distal portion, and a thermal damaging agent delivering lumen extending within at least a distal portion of the shaft. The device has at least one discharge port in the distal portion of the elongate shaft in fluid communication with the thermal damaging agent delivering inner lumen. A thermal damaging agent generator is in fluid communication with the thermal damaging agent delivery lumen in the elongate shaft and is configured for generating a thermal damaging agent at a temperature above 400C to the tissue at the targeted region to render the region essentially non¬ functional. Preferably the device also includes an occluding member disposed on a distal portion of the shaft to occlude the airway passage proximal to the delivery location of the thermal damaging agent.
[0010] In one embodiment the device includes an elongate shaft having a proximal portion, a distal portion, and a vapor delivering inner lumen extending within at least the distal portion of the shaft. The device has at least one discharge port in the distal portion of the elongate shaft in fluid communication with the vapor delivering inner lumen configured to deliver condensable vapor to the target region. A condensable vapor generator is provided in fluid communication with the vapor delivering lumen of the elongate shaft for generating a condensable vapor at a temperature above 400C to thermally damage tissue at the targeted region sufficiently to terminate blood flow and air flow to the targeted region. Preferably the device also includes an occluding member disposed on a distal portion of the shaft. The delivered condensable vapor is generally about 40° to 80° C, and preferably is about 50° to about 60° C. The condensable vapor is delivered to the targeted region for a period of about 5 seconds to about 10 minutes, preferably about 5 seconds to about 10 seconds. Suitable liquids for forming the condensable vapor includes water based fluids and perfluorocarbon
[0011] In addition to the treatment of COPD, other conditions can be treated, for example by applying the methods and devices described to pre-cancerous lesions, cancer tumors, or lung nodules. As will be recognized by those skilled in the art, reducing the total volume of a patient's lung, especially an emphysematous lung, can be an effective treatment for COPD.
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1A illustrates a method for treating a patient's lung embodying features of the invention.
[0013] Figure 1 B is an enlarged view of an air sac and alveoli within the patient's lung shown in Figure 1A...
[0014] Figure 2 is a longitudinal cross sectional view of the device shown in Figure 2.
[0015] Figures 3A is a transverse cross sectional view of the device shown in Figure 2, taken along lines 3A-3A. [0016] Figure 3B is a transverse cross sectional view of the device shown in
Figure 2, taken along lines 3B-3B.
[0017] Figure 4 is an elevational view, partially in perspective, of a system embodying features of the invention.
[0018] Figure 5A is an elevational view of a vapor generator connected to the device shown in Figure 2.
[0019] Figure 5B is an elevational view of a vapor generator connected to the device shown in Figure 2 which has a cartridge for storing vaporizable fluid.
[0020] Figure 5C is an elevational view of a vapor generator connected to the device shown in Figure 2 which is connected to a hand held operator or pistol grip handle.
DETAILED DESCRIPTION OF THE INVENTION
[0021] Figure 1 illustrates a method for treating a patient's lung 10 embodying features of the invention that includes delivering a condensable vapor 12 to tissue defining an air sac or alveoli 14 within a patient's lung 10 at a temperature above body temperature, preferably about 400C to about 800C, preferably about 50°C to about 60°C at atmospheric pressures, so as to damage the tissue of the air sac or alveoli 14, the tissue of terminal bronchioles 16 and tissue of collateral passageways 18. Such tissue damage renders the treated region non-functional in that the blood flow and air flow in the treated region is terminated. The treated region will no long inflate.
[0022] The method includes delivering the condensable vapor through an airway 20 of the lung to the targeted lung region. Preferably the airway 20 is a bronchial passageway such as segmental bronchi, and most preferably a sub segmental bronchi 20. [0023] The condensable vapor 12 serves to rapidly heat the targeted lung region as the vapor 12 is delivered and induces tissue collapse, shrinkage, neointima hyperplasia, necrosis and fibrosis (collectively referred to herein as "bioeffects") of the targeted lung region. Such bioeffects render the target lung region non¬ functioning.
[0024] The method may also include applying a vacuum to the targeted region after delivery of the condensable vapor to further supplement tissue contraction and collapse caused by introduction of the condensable vapor 12. The vacuum generated in the targeted region is about 1 to about 50 mm Hg, preferably about 10 to about 30 mm Hg to effectively collapse the targeted region. The vacuum may also facilitate aspiration of any residual vapor or liquid.
[0025] In general the vapor is applied into the targeted region through an airway for anywhere from 5 seconds to 10 minutes or longer. Preferably the condensable vapor is delivered for a short period of time, about 5 seconds to 10 seconds. Because tissue heating and the resulting damage is rapid using energetic vapor, short vapor application times are preferred. In longer procedures, less vapor may be used to cause gradual tissue bioeffects or to treat larger regions or volumes of tissue. Separate procedures may be utilized for separate regions to be treated. [0026] The condensable vapor 12 maybe generated from a liquid, for example, sterile water or other fluids such as perfluorocarbons, having relatively high liquid- gas phase-change temperatures, i.e. boiling points, preferably temperatures well above body temperature. In addition, preferably the condensable vapor 12 is at a temperature sufficient to increase the temperature of the surrounding lung parenchyma to cause damage, for example, above at least 400C. [0027] In one method of the invention the condensable vapor 12 additionally includes a detectable substance, such as a dye, preferably a biocompatible dye, to detect movement of the condensable vapor 12 and the affected lung regions. Alternatively or in conjunction with the visually detectable substance, diagnostic ultrasound, endoscopic and other conventional visualization techniques are used to monitor the vapor treatment and resulting tissue effects during and after treatment. [0028] In another method embodying features of the invention, the condensable vapor 12 is delivered with microparticulates. Suitable microparticulates include talc, calcium carbonate, antibiotics such as tetracycline and other penicillin derivates, or other particulate substances which induce fibrosis or cause necrosis of the lung tissue.
[0029] In another method embodying features of the invention the condensable vapor 12 includes a treatment agent such as an anesthetic or painkillers to alleviate patient discomfort and pain during the treatment. A painkiller, such as lidocane in powder or liquid form, preferably is used or mixed with a condensable vapor 12. Alternatively, pain killers may be delivered to the entire lung, or just to the targeted lung region. Patient preparation with pain medication before, during, and after the procedure is preferred in order to allow treatment using the present invention without the need for general anesthesia.
[0030] In another method embodying features of the invention helium or carbon dioxide is delivered in addition to the vapor 12 to lower the temperature of the vapor 12.
[0031] A method of the invention includes occluding the airway of a lung proximal to the area where the condensable vapor 12 is delivered. In some embodiments, to prevent condensable vapor from entering and damaging adjacent airways and lung regions, the adjacent airways are filled with a fluid, such as saline. Airways leading to untargeted lung regions may be obstructed to prevent vapor flow therein. [0032] In one method embodying features of the invention high intensity focused ultrasound (HIFU) energy is delivered to damage lung tissue such as the tissue of an air sac or alveoli in the lung. Preferably suitable ultrasound transducers that are capable of delivering high intensity focused ultrasound (HIFU), generally between about 100-10,000 W/cm2 at a focal spot.
[0033] The HIFU energy is delivered in amounts sufficient to cause contraction of lung tissue. Because HIFU can be tightly controlled, the ultrasound energy can be specifically targeted to the epithelium, smooth muscle layer, or collagen layer. Delivery of the HIFU energy can also serve to initiate a healing response (including neointima hyperplasia) which further serves to occlude the passageway. The method can include a wave guide to direct the HIFU sound waves to the intended treatment site. Additionally a vacuum may be applied prior the HIFU to draw down the airway or air sacs. Alternatively the vacuum may be applied after delivery of the HIFU energy as in the previously discussed embodiment to further supplement tissue contraction and collapse of the terminal bronchioles, air sacs and collateral passageways caused by introduction of the ultrasound energy. [0034] In another embodiment, an ultrasound absorptive material, such as a liquid or gel, can be eluted into the airway of the lung. The absorptive material is heated by the HIFU energy in order to thermally damage the surrounding tissue, resulting in contraction of the airway and or neointima hyperplasia, which will occlude the airway and or damage the air sacs of the lung. [0035] In an alternative embodiment, RF energy can be delivered to a desired location within a patient's lung to damage lung tissue but this usually requires a conductive fluid in contact with the lung tissue for effective ablation. [0036] Figure 2 depicts a system 22 embodying features of the invention including an elongate shaft 24 having a distal portion 26 and a proximal portion 28. Figure 2 is a longitudinal cross sectional view of the elongate shaft 24 and Figures 3A and 3B show transverse cross sectional views of the elongate shaft along the lines 3A-3A and lines 3B-3B shown in Figure 2. The elongated shaft 24 has at least one discharge port 30 in the distal portion 26 of the shaft configured to discharge condensable vapor 12 and a vapor delivering lumen 32 disposed within the elongate shaft 24 in fluid communication with the discharge port 30. A vapor generator 34 is connected to the lumen 32 of the elongate shaft.
[0037] The elongate shaft 24 also contains a vacuum lumen 36 which is configured to be connected to a vacuum source for application of a vacuum through vacuum port 38 in the distal portion 26 of the elongate shaft. [0038] The elongated shaft 24 is also provided with an inflation lumen 40 which leads to the inflation port 42. Port 42 opens to the interior 44 of the inflatable balloon 46 which is secured to the distal portion 26 of the shaft. The inflation device 48 may be a conventional syringe. The occluding member 46 is preferably expandable, compliant, and is configured to prevent vapor flow proximal to the location of the member. Suitable balloon materials include silicone or latex. The exterior of the working surface of the inflatable balloon 46 is preferably provided with a knurled or roughened surface to better engage the airway walls and prevent recoil when the condensable vapor is delivered to the target location. [0039] A venting system may be included with the device to ensure that high pressure does not exceed suitable limits. The venting system includes a venting lumen 50 in the shaft 24 which is in fluid communication with the port 52 in the distal end of the shaft 24. The venting mechanism can be a pressure actuated relief valve 54.
[0040] The device 22 also includes a temperature sensor 56, for example a thermocouple, located on the distal portion 26 of the elongate shaft 24 to monitor the surrounding temperature. When the temperature is too high, the lung region is brought back to normal temperatures with a lavage or washout procedure to facilitate removal of residual vapor.
[0041] The device 22 preferably includes a pressure sensor 58 on the distal portion 26 of the elongate shaft 24 to detect pressure within the targeted lung region. The pressure sensor 58 communicates with a pressure gauge 60 on the proximal portion 28 of the elongate shaft 24. The pressure sensing system may be tied in with the venting system to ensure that preset pressure limits are not exceeded during vapor delivery. Over inflation of the target region could lead to air leaks and tears in the lung pleura.
[0042] A suitable flow meter (not shown) may be included to monitor vapor flow to the targeted region of the patient's lung.
[0043] As shown in Figure 4 the elongate shaft 24 is configured to be delivered through the working channel (not shown) of an endoscope 62, preferably a bronchoscope. The working channel of the endoscope 62 is preferably between about 1.5 mm and 3.5 mm. The endoscope 62 is connected to an endoscope controller 64 and an endoscope monitor 66. Preferably, the distal portion 26 of the elongate shaft 24 is flexible to facilitate advancement of the elongate shaft in the working channel of the endoscope 56, while the proximal portion 28 is sufficiently rigid for good pushability of the shaft through and out of a distal opening of the endoscope. The distal portion 26 of the shaft 24 is about 1-6 French, the occluding balloon when inflated is larger than the working channel of the endoscope and is typically about 8 French. A suitable endoscope is the Olympus LF-TP bronchoscope.
[0044] Alternatively or in addition to the use of the occluding member 46, airways adjacent the delivery airway can be obstructed, for example, with a fluid such as saline. The fluid in the adjacent airways prevents condensable vapor 12 from entering into other lung regions which are not targeted for treatment and prevents damage of the adjacent regions.
[0045] Preferably the vapor generator 34, as shown in Figure 5A, is external to the elongate shaft 24 and stores the liquid supply. The vapor generator 34 has an outer housing 72 which houses internal structures including a liquid chamber 74 and an inner vapor conduit 76. Liquid may be loaded directly into the liquid chamber. The inner vapor conduit 76 extends from the liquid chamber 74 of the vapor generator 34 to the proximal portion 26 of the first lumen 32 and receives the condensable vapor 12 from the liquid chamber 74 a via an inlet port 78. The vapor generator 34 couples to the elongate shaft 24 via a luer fitting or similar mechanism. The liquid chamber 74 has heating elements such as resistive heating elements, or a RF heater or the like for vaporizing liquid inside the liquid chamber to a condensable vapor. When the liquid is vaporized, the vapor travels from the liquid chamber 74 through the inner vapor conduit 76 and exits into the proximal portion of the vapor lumen 32 of the elongate shaft 24 of the device. [0046] Alternatively, as shown in Figure 5B the vapor generator includes a cartridge compartment 80 which receives a cartridge 82 in fluid communication with the lumen 32 and containing a predetermined amount of liquid for vaporizing. The cartridge 82 is configured to preferably snap-fit into the compartment 80. When the vapor generator 34 is activated the fluid in the cartridge 82 is heated to a vapor. The condensable vapor 12 is then delivered to the proximal end of the first lumen 32. A predetermined volume or amount of vapor pressure to be delivered to a patient's lung 10 can be determined or calculated based on diagnostic evaluations or parameters of the patient before the treatment procedure, such as forced expiratory volume (FEV) or other lung function and capacity indicators. [0047] In one embodiment, the vapor generator 34, as shown in Figure 5C has an inner vapor conduit 76 which extends into a generator tube 84. The generator tube 84 connects to a pistol grip handle 86 which is configured to couple to the proximal portion 26 of the elongate shaft. The pistol grip handle 86 can be used to activate heating of the vapor 12 within the liquid chamber 74 of the vapor generator 34. The condensable vapor travels from the vapor generator 34 to the pistol grip 86 and into the elongate shaft 24.
[0048] Alternatively, the vapor generator 34 can be disposed within the elongate shaft 24. The heating elements, for example an RF electrode or emitter such as a helical coil, may be embedded within the wall of the shaft, surrounding the lumen 32. The heater may be used as an alternative to the vapor generator 34 or to augment or further control the temperature of the vapor leaving the discharge port 30 from lumen 32.
[0049] Preferably, the elongate shaft 24 of the device 22 is heat insulated to avoid overheating of the elongate shaft 24 inside the endoscope 62. In one embodiment the elongate shaft 24 contains a liquid lumen (not shown) and a cooling fluid is delivered within this lumen to prevent overheating.
[0050] The condensable vapor 12 is a substance which is capable of rapidly heating a region of the lung to render the target region non-functioning where there is little or no blood flow or air flow within the region. Suitable condensable vapors 12 are selected from the group consisting of condensable vapors from aqueous based fluids, for example, sterile water, saline, contrast fluid, and other fluids such as perfluorocarbons, liquid antibiotics, and other liquids having high liquid-gas phase- change temperatures, i.e. boiling point, preferably above body temperature. In addition preferably the condensable vapor 12 is at a temperature sufficient to increase the temperature of the tissue at the target site to cause tissue damage. [0051] In another embodiment of the invention the condensable vapor 12 includes a detectable substance, such as a dye or a biocompatible dye, to allow the physician to visually track progress of treatment and which lung regions have been treated. Alternatively or in conjunction with the visually detectable material, diagnostic ultrasound, endoscopic and other conventional visualization techniques are used to monitor the condensable vapor treatment and resulting tissue effects during and after treatment.
[0052] In yet another embodiment the condensable vapor 12 comprises a treatment agent such as a pain-numbing substance or painkillers to alleviate patient discomfort and pain during the treatment. A painkiller, such as lidocane in aqueous powder or liquid form, preferably is used or mixed with a condensable vapor 12. Alternatively pain killers are delivered to the entire lung, or the targeted lung region. Preferably patient preparation with pain medication before, during, and after the procedure is preferred in order to allow treatment using the present invention without the need for general anesthesia. The device can include a drug delivery lumen in fluid communication with a drug delivery port in the distal portion of the elongate shaft. Painkillers or other drugs can be delivered to the desired area through the optional drug delivery lumen.
[0053] In yet another embodiment the elongate shaft 24 of device 22 has a helium or carbon dioxide delivery lumen (not shown) for delivering helium or carbon dioxide in addition to the vapor 12 to lower the temperature of the condensable vapor 12. [0054] While particular forms of the invention have been illustrated and described herein, it will be apparent that various modifications and improvements can be made to the invention. Moreover, individual features of embodiments of the invention may be shown in some drawings and not in others, but those skilled in the art will recognize that individual features of one embodiment of the invention can be combined with any or all the features of another embodiment. Accordingly, it is not intended that the invention be limited to the specific embodiments illustrated. It is therefore intended that this invention be defined by the scope of the appended claims as broadly as the prior art will permit.
[0055] Terms such as "element", "member", "device", "section", "portion", "component", "means", "steps" and words of similar import when used herein shall not be construed as invoking the provisions of 35 U.S.C §112(6) unless the following claims expressly use the terms "means" or "step" followed by a particular function without reference to a specific structure or action. All patents and all patent applications referred to above are hereby incorporated by reference in their entirety.

Claims

WHAT IS CLAIMED IS:
1. A system for treating a patient's lung comprising means for heating a liquid to form a condensable vapor and means for delivering the condensable agent to a targeted region of the patient's lung to raise the temperature of tissue in the targeted region sufficiently high to render the targeted region non-functional.
2. The system of claim 1 wherein tissue damage within the targeted region causes blood flow and air flow within the targeted region to be terminated.
3. The system of claim 1 wherein the condensable vapor damages at least one of the group consisting of tissue defining at least in part an air sac of the patient's targeted region, tissue of terminal bronchioles in the targeted region and collateral passageways in the targeted region.
4. The system of claim 1 wherein an airway of the patient's lung through which the thermal damaging agent is delivered is occluded proximal to a point where the thermal damaging agent enters the target region.
5. The system of claim 1 wherein the condensable vapor is at a temperature above 60° C.
6. The system of claim 1 wherein the condensable vapor is at a temperature above 80° C at atmospheric pressure.
7. The system of claim 1 wherein the condensable vapor is at a temperature above 100° C.
8. The system of claim 1 wherein condensable vapor is delivered to the target region for about 5 seconds to 10 minutes.
9. The system of claim 1 wherein the condensable vapor is delivered to the target region for about 5 seconds to about 10 seconds.
10. The system of claim 1 wherein the condensable vapor is a water vapor.
11. The system of claim 1 wherein the condensable vapor is a perfluorocarbon vapor.
12. The system of claim 1 wherein the condensable vapor is generated from a liquid having a liquid-gas-phase change temperature which is above 40° C at atmospheric pressure.
13. The system of claim 1 wherein the condensable vapor is generated from a liquid having a liquid-gas phase change temperature above 5O0C at atmospheric pressure.
14. The system of claim 1 wherein the condensable vapor is generated from a liquid having a liquid-gas phase change temperature over 1000C at atmospheric pressure.
15. The system of claim 1 wherein the condensable vapor is delivered with a detectable substance.
16. The system of claim 15 wherein the detectable substance is a dye.
17. The system of claim 15 wherein the detectable substance is biocompatible.
18. The system of claim 1 wherein the condensable vapor is delivered with microparticulates.
19. The system of claim 18 wherein the microparticulates are selected from the group consisting of talc, calcium carbonate, or antibiotics.
20. The system of claim 19 wherein the microparticulates induce fibrosis or necrosis of the lung tissue.
21. The system of claim 1 wherein the condensable vapor rapidly heats tissue at the target site.
22. The system of claim 1 wherein the condensable vapor is advanced to the target site through a bronchial passageway of the lung.
23. The system of claim 22 wherein the bronchial passageway is a sub- segmental bronchi of the lung.
24. The system of claim 1 wherein a vacuum is generated within the target site to facilitate collapse of tissue structures thereof.
25. The system of claim 24 wherein the tissue structures collapsed are at least one of the group consisting of an air sac of the patient's targeted region, terminal bronchioles in the targeted region and collateral passageways in the targeted region.
26 The system of claim 24 wherein the applied vacuum at the target site is about 50 to about 60 mm Hg.
27. The system of claim 24 wherein the applied vacuum at the target site is about 40 to about 50 mm Hg.
28. A device for delivering a thermal damaging agent to a targeted region of the patient's lung to raise the temperature of tissue in the targeted region sufficiently high to render the targeted region non-functional, comprising:
a. an elongate shaft having a proximal portion, a distal portion and a thermal damaging agent delivering inner lumen extending within at least the distal portion of the shaft; b. at least one discharge port in the distal portion of the elongate shaft in fluid communication with the thermal damaging agent delivering inner lumen configured to deliver the thermal damaging agent; c. a thermal damaging agent generator in fluid communication with the first lumen of the elongate shaft for generating a thermal damaging agent at a temperature above 60° C to thermally damage tissue at the targeted region.
29. The device of claim 28 wherein an occluding member is disposed on the distal shaft portion.
30. The device of claim 29 wherein the occluding member is expandable.
31. The device of claim 30 wherein the expandable occluding member is inflatable.
32. The device of claim 31 wherein the elongate shaft includes an inflation lumen, an inflation port which is in fluid communication with the inflation lumen and an interior of the inflatable occluding member.
33. The device of claim 32 wherein the inflatable occluding member is a balloon.
34. A system of treating a patient's lung comprising means to deliver a condensable vapor at a temperature above body temperature at atmospheric pressures to tissue defining at least in part an air sac within the patient's lung.
35. The system of claim 34 wherein the condensable vapor also damages at least one of the groups consisting of tissue of terminal bronchioles in the targeted region and tissue defining collateral passageways in the targeted region.
36. The system of claim 34 wherein an airway of the patient's lung through which the condensable vapor is delivered is occluded proximal to a point where the condensable vapor enters the target region.
37. The system of claim 34 wherein the condensable vapor is at a temperature above 600C.
38. The system of claim 34 wherein the condensable vapor is at a temperature above about 80° C.
39. The system of claim 34 wherein the condensable vapor is at a temperature above about 100° C.
40. The system of claim 34 wherein condensable vapor is delivered to the target region for about 5 seconds to 10 minutes.
41. The system of claim 34 wherein condensable vapor is delivered to the target region for about 5 seconds to about 10 seconds.
42. The system of claim 34 wherein the condensable vapor is water vapor.
43. The system of claim 34 wherein the condensable vapor is a perfluorocarbon vapor.
44. The system of claim 34 wherein the condensable vapor is generated from a liquid having a liquid-gas-phase change temperature above 40° C at atmospheric pressure.
45. The system, of claim 34 wherein the condensable vapor is generated from a liquid having a liquid-gas phase change temperature above 500C at atmospheric pressure.
46. The system of claim 34 wherein the condensable vapor is generated from a liquid having a liquid-gas phase change temperature over 100°C at atmospheric pressure.
47. The system of claim 34 wherein the condensable vapor is delivered with a detectable substance.
48. The system of claim 47 wherein the detectable substance is a dye.
49. The system of claim 47 wherein the detectable substance is biocompatible.
50. The system of claim 34 wherein the condensable vapor is delivered with microparticulates.
51. The system of claim 50 wherein the microparticulates are selected from the group consisting of talc, calcium carbonate, or antibiotics.
52. The system of claim 50 wherein the microparticulates induce fibrosis or necrosis of the lung tissue.
53. The system of claim 34 wherein the condensable vapor rapidly heats tissue at the target site.
54. The system of claim 34 wherein the condensable vapor is advanced to the target site through a bronchial passageway of the lung.
55. The system of claim 54 wherein the bronchial passageway is a segmental or a sub-segmental bronchi of the lung.
56. The system of claim 34 wherein a vacuum is generated within the target site to collapse tissue structures thereof.
57. The system of claim 56 wherein the tissue structures collapsed are at least one of the group consisting of tissue of terminal bronchioles in the targeted region and tissue of collateral passageways in the targeted region.
58. The system of claim 56 wherein the applied vacuum at the target site is about 50 to about 60 mm Hg.
59. The system of claim 56 wherein the applied vacuum at the target site is about 40 to about 50 mmHg.
60. The system of claim 34 wherein an airway of the lung through which the condensable vapor is delivered is occluded proximal to a point where the condensable vapor enters the target site.
61. A device for delivering a condensable vapor to a targeted region of a patient's lung to raise the temperature of tissue in the targeted region sufficiently high to render the targeted region non-functional, comprising: a. an elongate shaft having a proximal portion, a distal portion and a vapor delivering inner lumen extending within at least the distal portion of the shaft; b. at least one discharge port in the distal portion of the elongate shaft in fluid communication with the vapor delivering inner lumen configured to deliver the condensable vapor; and c. a condensable vapor generator in fluid communication with the vapor delivering lumen of the elongate shaft for generating a condensable vapor at a temperature above 60° C to thermally damage tissue at the target site sufficiently to terminate blood flow and air flow to the targeted region.
62. The device of claim 61 wherein an occluding member is disposed on the distal shaft portion.
63 The device of claim 62 wherein the occluding member is expandable.
64. The device of claim 63 wherein the expandable occluding member is inflatable.
65. The device of claim 64 wherein the elongate shaft includes an inflation lumen, an inflation port which is in fluid communication with the inflation lumen and an interior of the inflatable occluding member.
66. The device of claim 64 wherein the inflatable member is a balloon.
67. The device of claim 61 wherein the shaft has a second lumen disposed which has a proximal end configured to be connected to a vacuum source and which has a vacuum port on the distal end of the elongate shaft in fluid communication with the second lumen.
68. The device of claim 61 wherein the elongate shaft is configured to be delivered through a working channel of an endoscope.
69. The device of claim 68 wherein the endoscope has a working channel with a diameter of about 1.5 mm to about 3.5 mm.
70. The device of claim 61 wherein at least a portion of the elongate shaft is heat insulated.
71. The device of claim 61 wherein the elongate shaft contains a coolant lumen configured to contain a cooling fluid.
72. The device of claim 61 wherein a pressure sensor is mounted on the distal portion of the elongate shaft.
73. The device of claim 72 wherein a pressure gauge is provided on the proximal portion of the elongate shaft to display the pressure sensed by the pressure sensor.
74. The device of claim 73 wherein the pressure gauge is connected to a venting system having a venting port in the distal portion of the elongate shaft which is in fluid communication with a fourth lumen.
75 The device of claim 74 wherein the venting system and pressure gauge are configured to operate a feedback loop.
76. The device of claim 75wherein the pressure gauge is connected to a pressure controller.
77. The device of claim 61 wherein the elongate shaft has a flow sensor for measuring vapor flow through the elongated shaft.
78. The device of claim 77 wherein the flow meter is connected to a pressure controller.
79. The device of claim 61 wherein the elongate shaft has a temperature sensor located on the distal end of the elongate shaft.
80. The device of claim 79 wherein the temperature sensor is a thermocouple.
81. The device of claim 61 wherein the vapor generator has a supply of liquid which forms condensable vapor.
82. The device of claim 66 wherein the supply of liquid is located in the vapor generator.
83. The device of claim 62 wherein the vapor generator is disposed within the occluding member.
84. The device of claim 61 herein the vapor generator is external to the elongate shaft.
85. The device of claim 69 wherein the vapor generator has an outer housing which houses a liquid receiving chamber.
86. The device of claim 85 wherein an inner vapor conduit extends from the liquid chamber to the proximal end of the elongate shaft.
87. The device of claim 86 wherein the inner vapor conduit couples to the elongate shaft with a luer fitting.
88. The device of claim 87 wherein the inner vapor conduit receives the condensable vapor from the liquid chamber via an inlet port.
89. The device of claim 85 wherein heating elements are provided in the liquid receiving chamber.
90. The device of claim 89 wherein the heating elements in the liquid chamber are resistive heating elements.
91. The device of claim 61 wherein the vapor generator has a cartridge compartment which receives a cartridge containing a liquid within a liquid chamber thereof.
92. The device of claim 91 wherein the cartridge is configured to snap into place within the cartridge compartment.
93. The device of claim 91 wherein an inner vapor conduit extends into a generator tube which connects the liquid chamber of the cartridge to a pistol grip handle.
.
94. The device of claim 93 wherein the pistol grip handle is configured to attach to the proximal end of the elongate shaft.
95. A system for treating a patient's lung comprising means for generating a thermal damaging agent and means for delivering the thermal damaging agent to a targeted region of the patient's lung to raise the temperature of tissue in the targeted region sufficiently high to render the targeted region non-functional.
96. The system of claim 95 wherein thermal damaging agent is configured to damage tissue within the targeted region so as to cause blood flow and air flow within the targeted region to be terminated.
97. The system of claim 95 wherein the tissue damaging agent is configured to damage at least one of the group consisting of tissue defining at least in part an air sac of the patient's targeted region, tissue of terminal bronchioles in the targeted region and collateral passageways in the targeted region.
98. The system of claim 95 wherein the tissue damaging agent is a condensable vapor at a temperature greater than body temperature.
99. The system of claim 95 wherein the tissue damaging agent is high intensity focused ultrasound.
PCT/US2005/041651 2004-11-16 2005-11-16 Device and method for lung treatment WO2006055695A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP05823129A EP1833397A1 (en) 2004-11-16 2005-11-16 Device and method for lung treatment
CN2005800466068A CN101115448B (en) 2004-11-16 2005-11-16 Device and method for lung treatment
MX2007005937A MX2007005937A (en) 2004-11-16 2005-11-16 Device and method for lung treatment.
CA2587909A CA2587909C (en) 2004-11-16 2005-11-16 Device and method for lung treatment
BRPI0518437-1A BRPI0518437A2 (en) 2004-11-16 2005-11-16 lung treatment device and method
JP2007543222A JP5020824B2 (en) 2004-11-16 2005-11-16 Lung therapy apparatus and method

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62845104P 2004-11-16 2004-11-16
US60/628,451 2004-11-16
US64803605P 2005-01-27 2005-01-27
US60/648,036 2005-01-27

Publications (1)

Publication Number Publication Date
WO2006055695A1 true WO2006055695A1 (en) 2006-05-26

Family

ID=35929697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/041651 WO2006055695A1 (en) 2004-11-16 2005-11-16 Device and method for lung treatment

Country Status (10)

Country Link
US (5) US7913698B2 (en)
EP (2) EP1833397A1 (en)
JP (1) JP5020824B2 (en)
KR (1) KR20070108141A (en)
CN (1) CN101115448B (en)
BR (1) BRPI0518437A2 (en)
CA (1) CA2587909C (en)
ES (1) ES2645340T3 (en)
MX (1) MX2007005937A (en)
WO (1) WO2006055695A1 (en)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009398A1 (en) 2007-07-06 2009-01-15 Tsunami Medtech, Llc Medical system and method of use
WO2009026528A1 (en) * 2007-08-23 2009-02-26 Aegea Medical, Inc. Uterine therapy device and method
WO2009055410A1 (en) * 2007-10-22 2009-04-30 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
EP2265206A2 (en) * 2008-03-21 2010-12-29 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
US7913698B2 (en) 2004-11-16 2011-03-29 Uptake Medical Corp. Device and method for lung treatment
US8322335B2 (en) 2007-10-22 2012-12-04 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
US8585645B2 (en) 2006-11-13 2013-11-19 Uptake Medical Corp. Treatment with high temperature vapor
WO2014055675A1 (en) 2012-10-02 2014-04-10 Lutz Freitag Devices and methods for pulmonary diagnosis
WO2014070820A2 (en) 2012-11-02 2014-05-08 Lixiao Wang Chemical ablation formulations and methods of treatments for various diseases
US8858549B2 (en) 1998-03-27 2014-10-14 Tsunami Medtech, Llc Medical instruments and techniques for treating pulmonary disorders
US8900223B2 (en) 2009-11-06 2014-12-02 Tsunami Medtech, Llc Tissue ablation systems and methods of use
US8911430B2 (en) 2008-06-17 2014-12-16 Tsunami Medtech, Llc Medical probes for the treatment of blood vessels
US9113944B2 (en) 2003-01-18 2015-08-25 Tsunami Medtech, Llc Method for performing lung volume reduction
US9161801B2 (en) 2009-12-30 2015-10-20 Tsunami Medtech, Llc Medical system and method of use
US9433457B2 (en) 2000-12-09 2016-09-06 Tsunami Medtech, Llc Medical instruments and techniques for thermally-mediated therapies
US9468487B2 (en) 2001-12-07 2016-10-18 Tsunami Medtech, Llc Medical instrument and method of use
US9561068B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
US9561067B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
US9561066B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
US9662060B2 (en) 2011-10-07 2017-05-30 Aegea Medical Inc. Integrity testing method and apparatus for delivering vapor to the uterus
US9700365B2 (en) 2008-10-06 2017-07-11 Santa Anna Tech Llc Method and apparatus for the ablation of gastrointestinal tissue
US9743974B2 (en) 2010-11-09 2017-08-29 Aegea Medical Inc. Positioning method and apparatus for delivering vapor to the uterus
US9924992B2 (en) 2008-02-20 2018-03-27 Tsunami Medtech, Llc Medical system and method of use
US9943353B2 (en) 2013-03-15 2018-04-17 Tsunami Medtech, Llc Medical system and method of use
US9993290B2 (en) 2014-05-22 2018-06-12 Aegea Medical Inc. Systems and methods for performing endometrial ablation
US10064697B2 (en) 2008-10-06 2018-09-04 Santa Anna Tech Llc Vapor based ablation system for treating various indications
US10118007B2 (en) 2007-03-16 2018-11-06 Ventinova Technologies B.V. Jet ventilation catheter, in particular for ventilating a patient
US10179019B2 (en) 2014-05-22 2019-01-15 Aegea Medical Inc. Integrity testing method and apparatus for delivering vapor to the uterus
US10286191B2 (en) 2014-10-30 2019-05-14 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
US10537375B2 (en) 2015-04-24 2020-01-21 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
US10548653B2 (en) 2008-09-09 2020-02-04 Tsunami Medtech, Llc Methods for delivering energy into a target tissue of a body
US10675079B2 (en) 2000-12-09 2020-06-09 Tsunami Medtech, Llc Method for treating tissue
US10695126B2 (en) 2008-10-06 2020-06-30 Santa Anna Tech Llc Catheter with a double balloon structure to generate and apply a heated ablative zone to tissue
US11284931B2 (en) 2009-02-03 2022-03-29 Tsunami Medtech, Llc Medical systems and methods for ablating and absorbing tissue
US11331140B2 (en) 2016-05-19 2022-05-17 Aqua Heart, Inc. Heated vapor ablation systems and methods for treating cardiac conditions
US11331037B2 (en) 2016-02-19 2022-05-17 Aegea Medical Inc. Methods and apparatus for determining the integrity of a bodily cavity
US11806066B2 (en) 2018-06-01 2023-11-07 Santa Anna Tech Llc Multi-stage vapor-based ablation treatment methods and vapor generation and delivery systems

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674259B2 (en) * 2000-12-09 2010-03-09 Tsunami Medtech Medical instruments and techniques for thermally-mediated therapies
US8241274B2 (en) 2000-01-19 2012-08-14 Medtronic, Inc. Method for guiding a medical device
US20030050648A1 (en) 2001-09-11 2003-03-13 Spiration, Inc. Removable lung reduction devices, systems, and methods
US6592594B2 (en) 2001-10-25 2003-07-15 Spiration, Inc. Bronchial obstruction device deployment system and method
US20030181922A1 (en) 2002-03-20 2003-09-25 Spiration, Inc. Removable anchored lung volume reduction devices and methods
US20030216769A1 (en) 2002-05-17 2003-11-20 Dillard David H. Removable anchored lung volume reduction devices and methods
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US7617005B2 (en) * 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US7100616B2 (en) * 2003-04-08 2006-09-05 Spiration, Inc. Bronchoscopic lung volume reduction method
US7811274B2 (en) 2003-05-07 2010-10-12 Portaero, Inc. Method for treating chronic obstructive pulmonary disease
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7426929B2 (en) 2003-05-20 2008-09-23 Portaero, Inc. Intra/extra-thoracic collateral ventilation bypass system and method
US7252086B2 (en) 2003-06-03 2007-08-07 Cordis Corporation Lung reduction system
US7377278B2 (en) 2003-06-05 2008-05-27 Portaero, Inc. Intra-thoracic collateral ventilation bypass system and method
US7682332B2 (en) 2003-07-15 2010-03-23 Portaero, Inc. Methods to accelerate wound healing in thoracic anastomosis applications
US7533671B2 (en) 2003-08-08 2009-05-19 Spiration, Inc. Bronchoscopic repair of air leaks in a lung
US20050178389A1 (en) * 2004-01-27 2005-08-18 Shaw David P. Disease indications for selective endobronchial lung region isolation
US20060047291A1 (en) * 2004-08-20 2006-03-02 Uptake Medical Corporation Non-foreign occlusion of an airway and lung collapse
US8220460B2 (en) 2004-11-19 2012-07-17 Portaero, Inc. Evacuation device and method for creating a localized pleurodesis
US7824366B2 (en) 2004-12-10 2010-11-02 Portaero, Inc. Collateral ventilation device with chest tube/evacuation features and method
US20070032785A1 (en) 2005-08-03 2007-02-08 Jennifer Diederich Tissue evacuation device
US8104474B2 (en) 2005-08-23 2012-01-31 Portaero, Inc. Collateral ventilation bypass system with retention features
US7406963B2 (en) 2006-01-17 2008-08-05 Portaero, Inc. Variable resistance pulmonary ventilation bypass valve and method
US7691151B2 (en) 2006-03-31 2010-04-06 Spiration, Inc. Articulable Anchor
WO2007132449A2 (en) * 2006-05-11 2007-11-22 Yossi Gross Implantable respiration therapy device
US20080039746A1 (en) 2006-05-25 2008-02-14 Medtronic, Inc. Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions
EP2094207B1 (en) * 2006-11-13 2015-09-09 Uptake Medical Corp. High pressure and high temperature vapor catheters and systems
US7993323B2 (en) 2006-11-13 2011-08-09 Uptake Medical Corp. High pressure and high temperature vapor catheters and systems
US7985254B2 (en) 2007-01-08 2011-07-26 David Tolkowsky Endobronchial fluid exhaler devices and methods for use thereof
US8163034B2 (en) 2007-05-11 2012-04-24 Portaero, Inc. Methods and devices to create a chemically and/or mechanically localized pleurodesis
US7931641B2 (en) 2007-05-11 2011-04-26 Portaero, Inc. Visceral pleura ring connector
US8062315B2 (en) 2007-05-17 2011-11-22 Portaero, Inc. Variable parietal/visceral pleural coupling
US20090125010A1 (en) * 2007-07-06 2009-05-14 Sharkey Hugh R Uterine Therapy Device and Method
EP2641572B1 (en) 2007-10-12 2019-07-24 Spiration Inc. Valve loader method, system, and apparatus
US8043301B2 (en) * 2007-10-12 2011-10-25 Spiration, Inc. Valve loader method, system, and apparatus
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
WO2009105432A2 (en) 2008-02-19 2009-08-27 Portaero, Inc. Devices and methods for delivery of a therapeutic agent through a pneumostoma
US8336540B2 (en) 2008-02-19 2012-12-25 Portaero, Inc. Pneumostoma management device and method for treatment of chronic obstructive pulmonary disease
US8475389B2 (en) 2008-02-19 2013-07-02 Portaero, Inc. Methods and devices for assessment of pneumostoma function
ES2398052T5 (en) 2008-05-09 2021-10-25 Nuvaira Inc Systems for treating a bronchial tree
US8444635B2 (en) * 2008-11-19 2013-05-21 Samuel Victor Lichtenstein Methods for selectively heating tissue
US8347881B2 (en) 2009-01-08 2013-01-08 Portaero, Inc. Pneumostoma management device with integrated patency sensor and method
US8518053B2 (en) 2009-02-11 2013-08-27 Portaero, Inc. Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease
EP2493408B1 (en) 2009-10-27 2015-06-24 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
KR101820542B1 (en) 2009-11-11 2018-01-19 호라이라 인코포레이티드 Systems, apparatuses, and methods for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US8795241B2 (en) 2011-05-13 2014-08-05 Spiration, Inc. Deployment catheter
WO2013173481A2 (en) * 2012-05-18 2013-11-21 Holaira, Inc. Compact delivery pulmonary treatment systems and methods for improving pulmonary function
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
JP2015037505A (en) * 2013-08-19 2015-02-26 テルモ株式会社 Method for reducing lung capacity
US9782211B2 (en) 2013-10-01 2017-10-10 Uptake Medical Technology Inc. Preferential volume reduction of diseased segments of a heterogeneous lobe
US9968758B2 (en) 2014-03-21 2018-05-15 Boston Scientific Scimed, Inc. Devices and methods for treating a lung
WO2015143366A1 (en) 2014-03-21 2015-09-24 Boston Scientific Scimed, Inc. Devices and methods for lumen occlusion
US10052429B2 (en) 2014-05-29 2018-08-21 Boston Scientific Scimed, Inc. Devices and methods for lung volume reduction
US10485604B2 (en) 2014-12-02 2019-11-26 Uptake Medical Technology Inc. Vapor treatment of lung nodules and tumors
US10531906B2 (en) 2015-02-02 2020-01-14 Uptake Medical Technology Inc. Medical vapor generator
US20160287223A1 (en) * 2015-04-01 2016-10-06 Boston Scientific Scimed, Inc. Pulmonary biopsy devices
US10674982B2 (en) 2015-08-06 2020-06-09 Covidien Lp System and method for local three dimensional volume reconstruction using a standard fluoroscope
US10702226B2 (en) 2015-08-06 2020-07-07 Covidien Lp System and method for local three dimensional volume reconstruction using a standard fluoroscope
US10716525B2 (en) 2015-08-06 2020-07-21 Covidien Lp System and method for navigating to target and performing procedure on target utilizing fluoroscopic-based local three dimensional volume reconstruction
US10980737B1 (en) 2016-03-08 2021-04-20 Samuel Victor Lichtenstein System for treating unwanted tissue using heat and heat activated drugs
KR101776043B1 (en) 2016-03-18 2017-09-07 연세대학교 산학협력단 Carinal anchoring double lumen tube
CA3025213A1 (en) * 2016-05-25 2017-11-30 Samuel Victor Lichtenstein System for treating unwanted tissue
US11529190B2 (en) 2017-01-30 2022-12-20 Covidien Lp Enhanced ablation and visualization techniques for percutaneous surgical procedures
US11793579B2 (en) 2017-02-22 2023-10-24 Covidien Lp Integration of multiple data sources for localization and navigation
US11129673B2 (en) 2017-05-05 2021-09-28 Uptake Medical Technology Inc. Extra-airway vapor ablation for treating airway constriction in patients with asthma and COPD
US10699448B2 (en) 2017-06-29 2020-06-30 Covidien Lp System and method for identifying, marking and navigating to a target using real time two dimensional fluoroscopic data
US11344364B2 (en) 2017-09-07 2022-05-31 Uptake Medical Technology Inc. Screening method for a target nerve to ablate for the treatment of inflammatory lung disease
CN109464186B (en) 2017-09-08 2023-12-22 泽丹医疗股份有限公司 Device and method for treating lung tumors
US11350988B2 (en) 2017-09-11 2022-06-07 Uptake Medical Technology Inc. Bronchoscopic multimodality lung tumor treatment
USD845467S1 (en) 2017-09-17 2019-04-09 Uptake Medical Technology Inc. Hand-piece for medical ablation catheter
US10893843B2 (en) 2017-10-10 2021-01-19 Covidien Lp System and method for identifying and marking a target in a fluoroscopic three-dimensional reconstruction
US11419658B2 (en) 2017-11-06 2022-08-23 Uptake Medical Technology Inc. Method for treating emphysema with condensable thermal vapor
US11490946B2 (en) 2017-12-13 2022-11-08 Uptake Medical Technology Inc. Vapor ablation handpiece
US11364004B2 (en) 2018-02-08 2022-06-21 Covidien Lp System and method for pose estimation of an imaging device and for determining the location of a medical device with respect to a target
US11705238B2 (en) 2018-07-26 2023-07-18 Covidien Lp Systems and methods for providing assistance during surgery
US11109999B2 (en) * 2018-07-27 2021-09-07 Cooltech, Llc Device for removing heat, energy, and/or fluid from a living mammal
CN109330565B (en) * 2018-10-29 2020-04-24 山东大学 Optical fiber sensing probe for measuring alveolar air pressure
US11877806B2 (en) 2018-12-06 2024-01-23 Covidien Lp Deformable registration of computer-generated airway models to airway trees
US11801113B2 (en) 2018-12-13 2023-10-31 Covidien Lp Thoracic imaging, distance measuring, and notification system and method
US11617493B2 (en) 2018-12-13 2023-04-04 Covidien Lp Thoracic imaging, distance measuring, surgical awareness, and notification system and method
US11357593B2 (en) 2019-01-10 2022-06-14 Covidien Lp Endoscopic imaging with augmented parallax
US11625825B2 (en) 2019-01-30 2023-04-11 Covidien Lp Method for displaying tumor location within endoscopic images
US11744643B2 (en) 2019-02-04 2023-09-05 Covidien Lp Systems and methods facilitating pre-operative prediction of post-operative tissue function
US11653927B2 (en) 2019-02-18 2023-05-23 Uptake Medical Technology Inc. Vapor ablation treatment of obstructive lung disease
CN109998699A (en) * 2019-04-18 2019-07-12 吉林市萌鑫科技有限责任公司 A kind of hand-held therapeutic instrument
US11627924B2 (en) 2019-09-24 2023-04-18 Covidien Lp Systems and methods for image-guided navigation of percutaneously-inserted devices
WO2022067186A1 (en) * 2020-09-25 2022-03-31 University Of Cincinnati Method for pleurodesis and delivery of drugs to the lung and pleural space
CN112869865B (en) * 2021-01-11 2022-09-02 贵阳德漫多医疗科技有限公司 Skin heat stripping device

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620440A (en) * 1993-11-13 1997-04-15 Richard Wolf Gmbh Medical instrument for applying hot gas
WO2000011927A2 (en) * 1998-08-18 2000-03-09 Gennady Viktorovich Mamaev Method for dissecting tissues, device for simultaneously dissecting and coagulating the same and variants thereof
US6409723B1 (en) * 1999-04-02 2002-06-25 Stuart D. Edwards Treating body tissue by applying energy and substances
WO2002069821A1 (en) * 2001-03-06 2002-09-12 Thermemed Corp. Vaporous delivery of thermal energy to tissue sites
US6592594B2 (en) 2001-10-25 2003-07-15 Spiration, Inc. Bronchial obstruction device deployment system and method
US6679264B1 (en) 2000-03-04 2004-01-20 Emphasys Medical, Inc. Methods and devices for use in performing pulmonary procedures

Family Cites Families (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US408899A (en) 1889-08-13 Island
US1719750A (en) 1927-09-29 1929-07-02 Charles E Parkhurst Dental apparatus
US4026285A (en) * 1972-04-05 1977-05-31 Jackson Richard R Humidifier for air to be inhaled
US3880168A (en) 1973-12-21 1975-04-29 Robert A Berman Endotracheal tube
US4773410A (en) 1984-10-09 1988-09-27 Transpirator Technologies, Inc. Method and apparatus for the treatment of the respiratory track with vapor-phase water
US4917084A (en) 1985-07-31 1990-04-17 C. R. Bard, Inc. Infrared laser catheter system
US4793352A (en) 1986-02-07 1988-12-27 Eichenlaub John E Limited heat transfer device and method
US5112328A (en) * 1988-01-25 1992-05-12 Refractive Laser Research & Development Program, Ltd. Method and apparatus for laser surgery
US4915113A (en) 1988-12-16 1990-04-10 Bio-Vascular, Inc. Method and apparatus for monitoring the patency of vascular grafts
US5352512A (en) 1989-03-15 1994-10-04 The United States Of America As Represented By The Secretary Of The Air Force Microscopic tube material and its method of manufacture
US5011566A (en) * 1989-03-15 1991-04-30 The United States Of America As Represented By The Secretary Of The Air Force Method of manufacturing microscopic tube material
US5263951A (en) 1989-04-21 1993-11-23 Kerus Medical Systems Correction of the optical focusing system of the eye using laser thermal keratoplasty
US5006119A (en) 1989-05-25 1991-04-09 Engineering & Research Associates, Inc. Hollow core coaxial catheter
EP0491685A4 (en) 1989-08-28 1993-10-13 K. Michael Sekins Lung cancer hyperthermia via ultrasound and/or convection with perfluorocarbon liquids
US5562608A (en) * 1989-08-28 1996-10-08 Biopulmonics, Inc. Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
AU721086B2 (en) * 1989-08-28 2000-06-22 Alliance Pharmaceutical Corporation Lung treatments via ultrasound and/or convection with perfluorocarbon liquids
US5084043A (en) * 1990-01-12 1992-01-28 Laserscope Method for performing a percutaneous diskectomy using a laser
AU647533B2 (en) 1990-10-16 1994-03-24 Summit Technology, Inc. Laser thermokeratoplasty methods and apparatus
US6113722A (en) 1991-04-24 2000-09-05 The United States Of America As Represented By The Secretary Of Air Force Microscopic tube devices and method of manufacture
US6194066B1 (en) * 1991-04-24 2001-02-27 The United States Of America As Represented By The Secretary Of The Air Force Microscopic tube devices and method of manufacture
US5524620A (en) * 1991-11-12 1996-06-11 November Technologies Ltd. Ablation of blood thrombi by means of acoustic energy
US5331947A (en) 1992-05-01 1994-07-26 Shturman Cardiology Systems, Inc. Inflatable sheath for introduction of ultrasonic catheter through the lumen of a fiber optic endoscope
WO1994002077A2 (en) * 1992-07-15 1994-02-03 Angelase, Inc. Ablation catheter system
US5354331A (en) * 1992-07-15 1994-10-11 Schachar Ronald A Treatment of presbyopia and other eye disorders
KR0141224B1 (en) * 1993-10-11 1998-06-01 김광호 Rapid display device
US5462521A (en) 1993-12-21 1995-10-31 Angeion Corporation Fluid cooled and perfused tip for a catheter
US5503638A (en) 1994-02-10 1996-04-02 Bio-Vascular, Inc. Soft tissue stapling buttress
US5824703A (en) 1994-05-13 1998-10-20 Synthetic Blood International, Inc. Method of assisting normal breathing in a mammal having a lung disorder
US5591157A (en) * 1994-09-07 1997-01-07 Hennings; David R. Method and apparatus for tympanic membrane shrinkage
AU3761995A (en) 1994-10-03 1996-04-26 Heart Technology, Inc. Transluminal thrombectomy apparatus
US5783046A (en) 1994-11-28 1998-07-21 Gentech, Inc. Process and apparatus for the destructive distillation of rubber
US5755753A (en) * 1995-05-05 1998-05-26 Thermage, Inc. Method for controlled contraction of collagen tissue
US5992769A (en) 1995-06-09 1999-11-30 The Regents Of The University Of Michigan Microchannel system for fluid delivery
US5735811A (en) * 1995-11-30 1998-04-07 Pharmasonics, Inc. Apparatus and methods for ultrasonically enhanced fluid delivery
US6032077A (en) * 1996-03-06 2000-02-29 Cardiac Pathways Corporation Ablation catheter with electrical coupling via foam drenched with a conductive fluid
US5800482A (en) 1996-03-06 1998-09-01 Cardiac Pathways Corporation Apparatus and method for linear lesion ablation
IT1283090B1 (en) * 1996-06-04 1998-04-07 Imr Srl LOW PRESSURE SHELL CASTING PLANT, WITH INCREASED POTENTIALITY
US5986662A (en) 1996-10-16 1999-11-16 Vital Images, Inc. Advanced diagnostic viewer employing automated protocol selection for volume-rendered imaging
US5752965A (en) 1996-10-21 1998-05-19 Bio-Vascular, Inc. Apparatus and method for producing a reinforced surgical fastener suture line
US5827268A (en) 1996-10-30 1998-10-27 Hearten Medical, Inc. Device for the treatment of patent ductus arteriosus and method of using the device
US6694975B2 (en) * 1996-11-21 2004-02-24 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5906202A (en) * 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
US5782914A (en) 1996-11-29 1998-07-21 Bio-Vascular, Inc. Method for preparing heterogeneous tissue grafts
US6086582A (en) 1997-03-13 2000-07-11 Altman; Peter A. Cardiac drug delivery system
USRE41801E1 (en) 1997-03-31 2010-10-05 Nextreme Thermal Solutions, Inc. Thin-film thermoelectric device and fabrication method of same
US6273907B1 (en) 1997-04-07 2001-08-14 Broncus Technologies, Inc. Bronchial stenter
US6283988B1 (en) 1997-04-07 2001-09-04 Broncus Technologies, Inc. Bronchial stenter having expandable electrodes
US6634363B1 (en) 1997-04-07 2003-10-21 Broncus Technologies, Inc. Methods of treating lungs having reversible obstructive pulmonary disease
US6488673B1 (en) * 1997-04-07 2002-12-03 Broncus Technologies, Inc. Method of increasing gas exchange of a lung
US7992572B2 (en) * 1998-06-10 2011-08-09 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
US7027869B2 (en) * 1998-01-07 2006-04-11 Asthmatx, Inc. Method for treating an asthma attack
US5972026A (en) 1997-04-07 1999-10-26 Broncus Technologies, Inc. Bronchial stenter having diametrically adjustable electrodes
US7425212B1 (en) 1998-06-10 2008-09-16 Asthmatx, Inc. Devices for modification of airways by transfer of energy
US6083255A (en) 1997-04-07 2000-07-04 Broncus Technologies, Inc. Bronchial stenter
US6411852B1 (en) * 1997-04-07 2002-06-25 Broncus Technologies, Inc. Modification of airways by application of energy
US6200333B1 (en) 1997-04-07 2001-03-13 Broncus Technologies, Inc. Bronchial stenter
US5913856A (en) * 1997-05-19 1999-06-22 Irvine Biomedical, Inc. Catheter system having a porous shaft and fluid irrigation capabilities
US5957919A (en) * 1997-07-02 1999-09-28 Laufer; Michael D. Bleb reducer
US6139571A (en) 1997-07-09 2000-10-31 Fuller Research Corporation Heated fluid surgical instrument
US5855564A (en) 1997-08-20 1999-01-05 Aradigm Corporation Aerosol extrusion mechanism
US6130671A (en) 1997-11-26 2000-10-10 Vital Images, Inc. Volume rendering lighting using dot product methodology
US5964752A (en) 1998-02-02 1999-10-12 Stone; Kevin R. Articular cartilage surface shaping apparatus and method
DE19808590C2 (en) 1998-02-28 2003-03-20 Draeger Medical Ag respiratory humidifier
WO1999048540A1 (en) 1998-03-23 1999-09-30 Bio-Vascular, Inc. Implants and method of making
US6053909A (en) 1998-03-27 2000-04-25 Shadduck; John H. Ionothermal delivery system and technique for medical procedures
US6210404B1 (en) 1998-10-28 2001-04-03 John H. Shadduck Microjoule electrical discharge catheter for thrombolysis in stroke patients
US7674259B2 (en) * 2000-12-09 2010-03-09 Tsunami Medtech Medical instruments and techniques for thermally-mediated therapies
US6911028B2 (en) 1998-10-28 2005-06-28 John H. Shadduck Medical instrument working end and method for endoluminal treatments
US7892229B2 (en) * 2003-01-18 2011-02-22 Tsunami Medtech, Llc Medical instruments and techniques for treating pulmonary disorders
US6508816B2 (en) 1998-03-27 2003-01-21 John H. Shadduck Medical instrument working end creating very high pressure gradients
US8016823B2 (en) 2003-01-18 2011-09-13 Tsunami Medtech, Llc Medical instrument and method of use
US6669694B2 (en) 2000-09-05 2003-12-30 John H. Shadduck Medical instruments and techniques for highly-localized thermally-mediated therapies
US6493589B1 (en) 1998-05-07 2002-12-10 Medtronic, Inc. Methods and apparatus for treatment of pulmonary conditions
US6327505B1 (en) 1998-05-07 2001-12-04 Medtronic, Inc. Method and apparatus for rf intraluminal reduction and occlusion
US6589201B1 (en) 1998-06-04 2003-07-08 Alcon Manufacturing, Ltd. Liquefracture handpiece tip
US6579270B2 (en) 1998-06-04 2003-06-17 Alcon Manufacturing, Ltd. Liquefracture handpiece tip
US6179805B1 (en) 1998-06-04 2001-01-30 Alcon Laboratories, Inc. Liquefracture handpiece
US6398759B1 (en) 1998-06-04 2002-06-04 Alcon Manufacturing, Ltd. Liquefracture handpiece tip
US6676628B2 (en) 1998-06-04 2004-01-13 Alcon Manufacturing, Ltd. Pumping chamber for a liquefracture handpiece
US6599311B1 (en) 1998-06-05 2003-07-29 Broncus Technologies, Inc. Method and assembly for lung volume reduction
US6997189B2 (en) * 1998-06-05 2006-02-14 Broncus Technologies, Inc. Method for lung volume reduction
US7198635B2 (en) * 2000-10-17 2007-04-03 Asthmatx, Inc. Modification of airways by application of energy
US6099251A (en) 1998-07-06 2000-08-08 United Technologies Corporation Coolable airfoil for a gas turbine engine
US6296639B1 (en) 1999-02-12 2001-10-02 Novacept Apparatuses and methods for interstitial tissue removal
AU1442500A (en) * 1998-10-05 2000-04-26 Scimed Life Systems, Inc. Large area thermal ablation
ATE315948T1 (en) 1998-11-17 2006-02-15 Henri Mehier DEVICE FOR INTRODUCING A MEDICATION INTO A TISSUE MEMBRANE, IMPLANTATION DEVICE AND INJECTION DEVICE
US6458231B1 (en) 1999-03-17 2002-10-01 The United States Of America As Represented By The Secretary Of The Air Force Method of making microtubes with axially variable geometries
US6162232A (en) 1999-03-18 2000-12-19 Shadduck; John H. Instruments and techniques for high-velocity fluid abrasion of epidermal layers with skin cooling
US6156036A (en) 1999-06-11 2000-12-05 Alcon Laboratories, Inc. Surgical handpiece tip
US6287290B1 (en) * 1999-07-02 2001-09-11 Pulmonx Methods, systems, and kits for lung volume reduction
US7462162B2 (en) 2001-09-04 2008-12-09 Broncus Technologies, Inc. Antiproliferative devices for maintaining patency of surgically created channels in a body organ
WO2001010314A2 (en) 1999-08-05 2001-02-15 Broncus Technologies, Inc. Methods and devices for creating collateral channels in the lungs
US7422584B2 (en) 2002-07-05 2008-09-09 Broncus Technologies, Inc. Extrapleural airway device and method
US7422563B2 (en) 1999-08-05 2008-09-09 Broncus Technologies, Inc. Multifunctional tip catheter for applying energy to tissue and detecting the presence of blood flow
US7815590B2 (en) 1999-08-05 2010-10-19 Broncus Technologies, Inc. Devices for maintaining patency of surgically created channels in tissue
US6712812B2 (en) 1999-08-05 2004-03-30 Broncus Technologies, Inc. Devices for creating collateral channels
US7022088B2 (en) 1999-08-05 2006-04-04 Broncus Technologies, Inc. Devices for applying energy to tissue
US7175644B2 (en) * 2001-02-14 2007-02-13 Broncus Technologies, Inc. Devices and methods for maintaining collateral channels in tissue
US6610043B1 (en) 1999-08-23 2003-08-26 Bistech, Inc. Tissue volume reduction
US6312474B1 (en) 1999-09-15 2001-11-06 Bio-Vascular, Inc. Resorbable implant materials
WO2001026721A1 (en) 1999-10-14 2001-04-19 The Trustees Of Boston University Variable peak pressure ventilation method and system
US6398775B1 (en) 1999-10-21 2002-06-04 Pulmonx Apparatus and method for isolated lung access
US6885888B2 (en) * 2000-01-20 2005-04-26 The Cleveland Clinic Foundation Electrical stimulation of the sympathetic nerve chain
US6904909B2 (en) 2000-03-04 2005-06-14 Emphasys Medical, Inc. Methods and devices for use in performing pulmonary procedures
US6558385B1 (en) * 2000-09-22 2003-05-06 Tissuelink Medical, Inc. Fluid-assisted medical device
US6575929B2 (en) 2000-03-14 2003-06-10 Alcon Manufacturing, Ltd. Pumping chamber for a liquefaction handpiece
US6770070B1 (en) 2000-03-17 2004-08-03 Rita Medical Systems, Inc. Lung treatment apparatus and method
US8251070B2 (en) 2000-03-27 2012-08-28 Asthmatx, Inc. Methods for treating airways
US6755794B2 (en) 2000-04-25 2004-06-29 Synovis Life Technologies, Inc. Adjustable stylet
US6938619B1 (en) * 2000-06-13 2005-09-06 Scott Laboratories, Inc. Mask free delivery of oxygen and ventilatory monitoring
US6669692B1 (en) * 2000-08-21 2003-12-30 Biosense Webster, Inc. Ablation catheter with cooled linear electrode
US7031504B1 (en) 2000-09-26 2006-04-18 Vital Images, Inc. Image data based retrospective temporal selection of medical images
DE60025049T2 (en) 2000-10-17 2006-08-03 Asthmatx, Inc., Mountain View MODIFYING AIRWAYS BY EXERCISING ENERGY
US6585639B1 (en) 2000-10-27 2003-07-01 Pulmonx Sheath and method for reconfiguring lung viewing scope
US6527761B1 (en) * 2000-10-27 2003-03-04 Pulmonx, Inc. Methods and devices for obstructing and aspirating lung tissue segments
US7549987B2 (en) 2000-12-09 2009-06-23 Tsunami Medtech, Llc Thermotherapy device
US6653525B2 (en) 2001-01-18 2003-11-25 The Brigham And Women's Hospital, Inc. Prosthetic device for respiratory patients
US7798147B2 (en) 2001-03-02 2010-09-21 Pulmonx Corporation Bronchial flow control devices with membrane seal
DE60230261D1 (en) 2001-05-23 2009-01-22 Vital Images Inc COVER MASKING FOR VOLUME PRESENTATION AN OBJECT ORDER
US6860847B2 (en) 2001-07-10 2005-03-01 Spiration, Inc. Constriction device viewable under X ray fluoroscopy
US6776765B2 (en) 2001-08-21 2004-08-17 Synovis Life Technologies, Inc. Steerable stylet
US7708712B2 (en) * 2001-09-04 2010-05-04 Broncus Technologies, Inc. Methods and devices for maintaining patency of surgically created channels in a body organ
CA2462093C (en) * 2001-10-05 2012-02-28 Research Triangle Institute Phonon-blocking, electron-transmitting low-dimensional structures
CA2458595C (en) 2001-10-11 2007-12-04 Peter M. Wilson Bronchial flow control devices and methods of use
US8444636B2 (en) 2001-12-07 2013-05-21 Tsunami Medtech, Llc Medical instrument and method of use
US6929637B2 (en) 2002-02-21 2005-08-16 Spiration, Inc. Device and method for intra-bronchial provision of a therapeutic agent
FR2836047B1 (en) 2002-02-21 2004-04-02 Henri Mehier FACILITY FOR DELIVERING CALORIES IN ALL OR PART OF A HUMAN OR ANIMAL CELLULAR FABRIC
AU2003220124A1 (en) * 2002-03-08 2003-09-22 Emphasys Medical, Inc. Methods and devices for inducing collapse in lung regions fed by collateral pathways
US20030181922A1 (en) 2002-03-20 2003-09-25 Spiration, Inc. Removable anchored lung volume reduction devices and methods
US7128748B2 (en) 2002-03-26 2006-10-31 Synovis Life Technologies, Inc. Circular stapler buttress combination
JP2005522274A (en) 2002-04-17 2005-07-28 スーパー ディメンション リミテッド Techniques for navigating to targets in endoscopic and bifurcated structures
US6588613B1 (en) * 2002-05-13 2003-07-08 The United States Of America As Represented By The Secretary Of The Air Force Baby-feeding nipple
US20040089306A1 (en) * 2002-05-28 2004-05-13 Ronald Hundertmark Devices and methods for removing bronchial isolation devices implanted in the lung
US7819908B2 (en) 2002-06-17 2010-10-26 Aeris Therapeutics, Inc. Compositions and methods for reducing lung volume
CA2530042C (en) 2002-06-17 2012-04-03 Aeris Therapeutics, Inc. Compositions and methods for reducing lung volume
US7192400B2 (en) 2002-10-24 2007-03-20 Synovis Life Technologies, Inc. Device and method for vascular monitoring
US7913688B2 (en) * 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US6918869B2 (en) 2002-12-02 2005-07-19 Scimed Life Systems System for administering a combination of therapies to a body lumen
US7083612B2 (en) 2003-01-15 2006-08-01 Cryodynamics, Llc Cryotherapy system
US7144588B2 (en) 2003-01-17 2006-12-05 Synovis Life Technologies, Inc. Method of preventing surgical adhesions
US7100616B2 (en) * 2003-04-08 2006-09-05 Spiration, Inc. Bronchoscopic lung volume reduction method
US20040226556A1 (en) * 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7377278B2 (en) 2003-06-05 2008-05-27 Portaero, Inc. Intra-thoracic collateral ventilation bypass system and method
US7144402B2 (en) 2003-06-16 2006-12-05 Synovis Life Technologies, Inc. Vascular clamp
US7235070B2 (en) * 2003-07-02 2007-06-26 St. Jude Medical, Atrial Fibrillation Division, Inc. Ablation fluid manifold for ablation catheter
US20050016530A1 (en) 2003-07-09 2005-01-27 Mccutcheon John Treatment planning with implantable bronchial isolation devices
US8002740B2 (en) 2003-07-18 2011-08-23 Broncus Technologies, Inc. Devices for maintaining patency of surgically created channels in tissue
EP2316328B1 (en) 2003-09-15 2012-05-09 Super Dimension Ltd. Wrap-around holding device for use with bronchoscopes
WO2005025635A2 (en) 2003-09-15 2005-03-24 Super Dimension Ltd. System of accessories for use with bronchoscopes
US20050171396A1 (en) 2003-10-20 2005-08-04 Cyberheart, Inc. Method for non-invasive lung treatment
US7347859B2 (en) * 2003-12-18 2008-03-25 Boston Scientific, Scimed, Inc. Tissue treatment system and method for tissue perfusion using feedback control
US8100123B2 (en) * 2004-01-22 2012-01-24 Thermocure, Inc. Respiratory system for inducing therapeutic hypothermia
US20050178389A1 (en) * 2004-01-27 2005-08-18 Shaw David P. Disease indications for selective endobronchial lung region isolation
US7476242B2 (en) 2004-01-30 2009-01-13 Ams Research Corporation Electrically heated/phase change probe temperature control
US7549984B2 (en) 2004-06-16 2009-06-23 Pneumrx, Inc. Method of compressing a portion of a lung
AU2005258739B2 (en) 2004-07-07 2010-10-28 Covidien Lp Methods for localized intra-body treatment of tissue
US20060047291A1 (en) * 2004-08-20 2006-03-02 Uptake Medical Corporation Non-foreign occlusion of an airway and lung collapse
US20060130830A1 (en) * 2004-09-07 2006-06-22 Uptake Medical Corporation Intra-bronchial implants for improved attachment
US7906124B2 (en) * 2004-09-18 2011-03-15 Asthmatx, Inc. Inactivation of smooth muscle tissue
US7997266B2 (en) 2004-10-04 2011-08-16 Koninklijke Philips Electronics N.V. System and method for airway manipulation
US7949407B2 (en) * 2004-11-05 2011-05-24 Asthmatx, Inc. Energy delivery devices and methods
WO2006052940A2 (en) 2004-11-05 2006-05-18 Asthmatx, Inc. Medical device with procedure improvement features
JP2008519669A (en) 2004-11-12 2008-06-12 アスマティックス，インコーポレイテッド Apparatus and method for improved energy delivery
AU2005304632C1 (en) 2004-11-12 2010-11-04 Boston Scientific Scimed, Inc. Improved energy delivery devices and methods
US20070093802A1 (en) * 2005-10-21 2007-04-26 Danek Christopher J Energy delivery devices and methods
KR20070108141A (en) * 2004-11-16 2007-11-08 로버트 엘 베리 Device and method for lung treatment
US20060162731A1 (en) 2004-11-16 2006-07-27 Pulmonx Pulmonary occlusal stent delivery catheter, loading system and methods of use
US20070068530A1 (en) * 2004-11-19 2007-03-29 Pacey John A Secretion clearing ventilation catheter and airway management system
AU2006209044A1 (en) 2005-01-27 2006-08-03 Super Dimension Ltd. Endoscope with miniature imaging arrangement
CA2605360C (en) 2005-04-21 2017-03-28 Asthmatx, Inc. Control methods and devices for energy delivery
US20070032785A1 (en) 2005-08-03 2007-02-08 Jennifer Diederich Tissue evacuation device
US7628789B2 (en) 2005-08-17 2009-12-08 Pulmonx Corporation Selective lung tissue ablation
US20070092864A1 (en) * 2005-09-30 2007-04-26 The University Of Iowa Research Foundation Treatment planning methods, devices and systems
US20070109299A1 (en) * 2005-11-15 2007-05-17 Vital Images, Inc. Surface-based characteristic path generation
US7993323B2 (en) 2006-11-13 2011-08-09 Uptake Medical Corp. High pressure and high temperature vapor catheters and systems
US8585645B2 (en) * 2006-11-13 2013-11-19 Uptake Medical Corp. Treatment with high temperature vapor
EP2170198B1 (en) 2007-07-06 2015-04-15 Tsunami Medtech, LLC Medical system
US8322335B2 (en) * 2007-10-22 2012-12-04 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
BRPI0818239A2 (en) * 2007-10-22 2017-12-05 Uptake Medical Corp determination of patient-specific treatment parameters and steam delivery
US8095827B2 (en) * 2007-11-16 2012-01-10 International Business Machines Corporation Replication management with undo and redo capabilities
US20130267939A1 (en) 2012-04-10 2013-10-10 Robert Lawrence Barry Methods and Apparatus for Ablating Lung Nodules with Vapor
US9782211B2 (en) 2013-10-01 2017-10-10 Uptake Medical Technology Inc. Preferential volume reduction of diseased segments of a heterogeneous lobe
US10485604B2 (en) * 2014-12-02 2019-11-26 Uptake Medical Technology Inc. Vapor treatment of lung nodules and tumors
US11419658B2 (en) * 2017-11-06 2022-08-23 Uptake Medical Technology Inc. Method for treating emphysema with condensable thermal vapor
WO2019222741A1 (en) * 2018-05-18 2019-11-21 Pneumrx, Inc. Lung volume reduction apparatus and methods

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620440A (en) * 1993-11-13 1997-04-15 Richard Wolf Gmbh Medical instrument for applying hot gas
WO2000011927A2 (en) * 1998-08-18 2000-03-09 Gennady Viktorovich Mamaev Method for dissecting tissues, device for simultaneously dissecting and coagulating the same and variants thereof
US6409723B1 (en) * 1999-04-02 2002-06-25 Stuart D. Edwards Treating body tissue by applying energy and substances
US6679264B1 (en) 2000-03-04 2004-01-20 Emphasys Medical, Inc. Methods and devices for use in performing pulmonary procedures
WO2002069821A1 (en) * 2001-03-06 2002-09-12 Thermemed Corp. Vaporous delivery of thermal energy to tissue sites
US20020177846A1 (en) 2001-03-06 2002-11-28 Mulier Peter M.J. Vaporous delivery of thermal energy to tissue sites
US6592594B2 (en) 2001-10-25 2003-07-15 Spiration, Inc. Bronchial obstruction device deployment system and method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MORICE R C; ECE T; ECE F; KEUS L: "Endobronchial argon plasma coagulation for treatment of hemoptysis and neoplastic airway obstruction.", CHEST, vol. 119, no. 3, March 2001 (2001-03-01), United Stets, pages 781 - 787, XP002371015 *
See also references of EP1833397A1

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9204889B2 (en) 1998-03-27 2015-12-08 Tsunami Medtech, Llc Medical instrument and method of use
US8858549B2 (en) 1998-03-27 2014-10-14 Tsunami Medtech, Llc Medical instruments and techniques for treating pulmonary disorders
US9615875B2 (en) 2000-12-09 2017-04-11 Tsunami Med Tech, LLC Medical instruments and techniques for thermally-mediated therapies
US10675079B2 (en) 2000-12-09 2020-06-09 Tsunami Medtech, Llc Method for treating tissue
US10524847B2 (en) 2000-12-09 2020-01-07 Tsunami Medtech, Llc Medical instruments and techniques for thermally-mediated therapies
US9433457B2 (en) 2000-12-09 2016-09-06 Tsunami Medtech, Llc Medical instruments and techniques for thermally-mediated therapies
US9468487B2 (en) 2001-12-07 2016-10-18 Tsunami Medtech, Llc Medical instrument and method of use
US9113944B2 (en) 2003-01-18 2015-08-25 Tsunami Medtech, Llc Method for performing lung volume reduction
US9907599B2 (en) 2003-10-07 2018-03-06 Tsunami Medtech, Llc Medical system and method of use
US7913698B2 (en) 2004-11-16 2011-03-29 Uptake Medical Corp. Device and method for lung treatment
US11839418B2 (en) 2004-11-16 2023-12-12 Uptake Medical Technology Inc. Device and method for lung treatment
US8585645B2 (en) 2006-11-13 2013-11-19 Uptake Medical Corp. Treatment with high temperature vapor
US10406308B2 (en) 2007-03-16 2019-09-10 Ventinova Technologies B.V. Jet ventilation catheter, in particular for ventilating a patient
US10118007B2 (en) 2007-03-16 2018-11-06 Ventinova Technologies B.V. Jet ventilation catheter, in particular for ventilating a patient
EP2170198A1 (en) * 2007-07-06 2010-04-07 Tsunami Medtech, LLC Medical system and method of use
US11207118B2 (en) 2007-07-06 2021-12-28 Tsunami Medtech, Llc Medical system and method of use
EP2170198A4 (en) * 2007-07-06 2011-03-30 Tsunami Medtech Llc Medical system and method of use
WO2009009398A1 (en) 2007-07-06 2009-01-15 Tsunami Medtech, Llc Medical system and method of use
US10154871B2 (en) 2007-08-23 2018-12-18 Aegea Medical Inc. Uterine therapy device and method
US8216217B2 (en) 2007-08-23 2012-07-10 Aegea Medical, Inc. Uterine therapy device and method
WO2009026528A1 (en) * 2007-08-23 2009-02-26 Aegea Medical, Inc. Uterine therapy device and method
US8221401B2 (en) 2007-08-23 2012-07-17 Aegea Medical, Inc. Uterine therapy device and method
US8197470B2 (en) 2007-08-23 2012-06-12 Aegea Medical, Inc. Uterine therapy device and method
US10758292B2 (en) 2007-08-23 2020-09-01 Aegea Medical Inc. Uterine therapy device and method
US11213338B2 (en) 2007-08-23 2022-01-04 Aegea Medical Inc. Uterine therapy device and method
US8221403B2 (en) 2007-08-23 2012-07-17 Aegea Medical, Inc. Uterine therapy device and method
US8322335B2 (en) 2007-10-22 2012-12-04 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
JP2011500281A (en) * 2007-10-22 2011-01-06 アップテイク・メディカル・コーポレイション Method for determining patient specific steam treatment and delivery parameters
US8734380B2 (en) 2007-10-22 2014-05-27 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
US8147532B2 (en) 2007-10-22 2012-04-03 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
WO2009055410A1 (en) * 2007-10-22 2009-04-30 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
US10595925B2 (en) 2008-02-20 2020-03-24 Tsunami Medtech, Llc Medical system and method of use
US9924992B2 (en) 2008-02-20 2018-03-27 Tsunami Medtech, Llc Medical system and method of use
EP2265206A4 (en) * 2008-03-21 2012-05-02 Uptake Medical Corp Determining patient-specific vapor treatment and delivery parameters
JP2011515161A (en) * 2008-03-21 2011-05-19 アップテイク・メディカル・コーポレイション Method for determining patient specific steam treatment and delivery parameters
EP2265206A2 (en) * 2008-03-21 2010-12-29 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
US11129664B2 (en) 2008-05-31 2021-09-28 Tsunami Medtech, Llc Systems and methods for delivering energy into a target tissue of a body
US11141210B2 (en) 2008-05-31 2021-10-12 Tsunami Medtech, Llc Systems and methods for delivering energy into a target tissue of a body
US11179187B2 (en) 2008-05-31 2021-11-23 Tsunami Medtech, Llc Methods for delivering energy into a target tissue of a body
US11284932B2 (en) 2008-05-31 2022-03-29 Tsunami Medtech, Llc Methods for delivering energy into a target tissue of a body
US11478291B2 (en) 2008-05-31 2022-10-25 Tsunami Medtech, Llc Methods for delivering energy into a target tissue of a body
US8911430B2 (en) 2008-06-17 2014-12-16 Tsunami Medtech, Llc Medical probes for the treatment of blood vessels
US10548653B2 (en) 2008-09-09 2020-02-04 Tsunami Medtech, Llc Methods for delivering energy into a target tissue of a body
US10842549B2 (en) 2008-10-06 2020-11-24 Santa Anna Tech Llc Vapor ablation system with a catheter having more than one positioning element and configured to treat pulmonary tissue
US10064697B2 (en) 2008-10-06 2018-09-04 Santa Anna Tech Llc Vapor based ablation system for treating various indications
US11589920B2 (en) 2008-10-06 2023-02-28 Santa Anna Tech Llc Catheter with a double balloon structure to generate and apply an ablative zone to tissue
US10842557B2 (en) 2008-10-06 2020-11-24 Santa Anna Tech Llc Vapor ablation system with a catheter having more than one positioning element and configured to treat duodenal tissue
US9561066B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
US10695126B2 (en) 2008-10-06 2020-06-30 Santa Anna Tech Llc Catheter with a double balloon structure to generate and apply a heated ablative zone to tissue
US11779430B2 (en) 2008-10-06 2023-10-10 Santa Anna Tech Llc Vapor based ablation system for treating uterine bleeding
US9561068B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
US10842548B2 (en) 2008-10-06 2020-11-24 Santa Anna Tech Llc Vapor ablation system with a catheter having more than one positioning element
US11813014B2 (en) 2008-10-06 2023-11-14 Santa Anna Tech Llc Methods and systems for directed tissue ablation
US11020175B2 (en) 2008-10-06 2021-06-01 Santa Anna Tech Llc Methods of ablating tissue using time-limited treatment periods
US9561067B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
US9700365B2 (en) 2008-10-06 2017-07-11 Santa Anna Tech Llc Method and apparatus for the ablation of gastrointestinal tissue
US11284931B2 (en) 2009-02-03 2022-03-29 Tsunami Medtech, Llc Medical systems and methods for ablating and absorbing tissue
US8900223B2 (en) 2009-11-06 2014-12-02 Tsunami Medtech, Llc Tissue ablation systems and methods of use
US9161801B2 (en) 2009-12-30 2015-10-20 Tsunami Medtech, Llc Medical system and method of use
US10499973B2 (en) 2010-08-13 2019-12-10 Tsunami Medtech, Llc Medical system and method of use
US11457969B2 (en) 2010-08-13 2022-10-04 Tsunami Medtech, Llc Medical system and method of use
US11160597B2 (en) 2010-11-09 2021-11-02 Aegea Medical Inc. Positioning method and apparatus for delivering vapor to the uterus
US9743974B2 (en) 2010-11-09 2017-08-29 Aegea Medical Inc. Positioning method and apparatus for delivering vapor to the uterus
US10238446B2 (en) 2010-11-09 2019-03-26 Aegea Medical Inc. Positioning method and apparatus for delivering vapor to the uterus
CN107242901A (en) * 2011-06-03 2017-10-13 维兰德·K·沙马 Method and apparatus for ablation of tissue
US9662060B2 (en) 2011-10-07 2017-05-30 Aegea Medical Inc. Integrity testing method and apparatus for delivering vapor to the uterus
US10881442B2 (en) 2011-10-07 2021-01-05 Aegea Medical Inc. Integrity testing method and apparatus for delivering vapor to the uterus
WO2014055675A1 (en) 2012-10-02 2014-04-10 Lutz Freitag Devices and methods for pulmonary diagnosis
EP2903514A4 (en) * 2012-10-02 2016-06-15 Lutz Freitag Devices and methods for pulmonary diagnosis
US11684417B2 (en) 2012-11-02 2023-06-27 Neurotronic, Inc. Chemical ablation formulations and methods of treatments for various diseases
EP4230162A1 (en) * 2012-11-02 2023-08-23 Neurotronic, Inc. Chemical ablation formulations and methods of treatments for various diseases
EP2914326B1 (en) * 2012-11-02 2023-08-16 Neurotronic, Inc. Chemical ablation formulations
US11517725B2 (en) 2012-11-02 2022-12-06 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
WO2014070820A2 (en) 2012-11-02 2014-05-08 Lixiao Wang Chemical ablation formulations and methods of treatments for various diseases
US11382689B2 (en) 2012-11-02 2022-07-12 Neurotronic, Inc. Chemical ablation formulations and methods of treatments for various diseases
US11672584B2 (en) 2013-03-15 2023-06-13 Tsunami Medtech, Llc Medical system and method of use
US11413086B2 (en) 2013-03-15 2022-08-16 Tsunami Medtech, Llc Medical system and method of use
US9943353B2 (en) 2013-03-15 2018-04-17 Tsunami Medtech, Llc Medical system and method of use
US10575898B2 (en) 2014-05-22 2020-03-03 Aegea Medical Inc. Systems and methods for performing endometrial ablation
US10299856B2 (en) 2014-05-22 2019-05-28 Aegea Medical Inc. Systems and methods for performing endometrial ablation
US11219479B2 (en) 2014-05-22 2022-01-11 Aegea Medical Inc. Integrity testing method and apparatus for delivering vapor to the uterus
US10179019B2 (en) 2014-05-22 2019-01-15 Aegea Medical Inc. Integrity testing method and apparatus for delivering vapor to the uterus
US9993290B2 (en) 2014-05-22 2018-06-12 Aegea Medical Inc. Systems and methods for performing endometrial ablation
US11648378B2 (en) 2014-10-30 2023-05-16 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
US10286191B2 (en) 2014-10-30 2019-05-14 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
US10758713B2 (en) 2014-10-30 2020-09-01 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
US10537375B2 (en) 2015-04-24 2020-01-21 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
US11331037B2 (en) 2016-02-19 2022-05-17 Aegea Medical Inc. Methods and apparatus for determining the integrity of a bodily cavity
US11331140B2 (en) 2016-05-19 2022-05-17 Aqua Heart, Inc. Heated vapor ablation systems and methods for treating cardiac conditions
US11806066B2 (en) 2018-06-01 2023-11-07 Santa Anna Tech Llc Multi-stage vapor-based ablation treatment methods and vapor generation and delivery systems
US11864809B2 (en) 2018-06-01 2024-01-09 Santa Anna Tech Llc Vapor-based ablation treatment methods with improved treatment volume vapor management

Also Published As

Publication number Publication date
US10806501B2 (en) 2020-10-20
CN101115448A (en) 2008-01-30
BRPI0518437A2 (en) 2008-11-18
ES2645340T3 (en) 2017-12-05
US20060161233A1 (en) 2006-07-20
US9050076B2 (en) 2015-06-09
US7913698B2 (en) 2011-03-29
EP2545874B1 (en) 2017-09-20
US11839418B2 (en) 2023-12-12
EP2545874A1 (en) 2013-01-16
JP2008523848A (en) 2008-07-10
CN101115448B (en) 2010-05-12
US9642668B2 (en) 2017-05-09
KR20070108141A (en) 2007-11-08
US20210000524A1 (en) 2021-01-07
JP5020824B2 (en) 2012-09-05
US20110172654A1 (en) 2011-07-14
EP1833397A1 (en) 2007-09-19
US20150230852A1 (en) 2015-08-20
MX2007005937A (en) 2007-09-11
CA2587909C (en) 2016-01-05
US20170231679A1 (en) 2017-08-17
CA2587909A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
US11839418B2 (en) Device and method for lung treatment
JP6559293B2 (en) Method and system for consistent, prepurable and safe cryospray treatment of airway tissue
CN107242901B (en) Method and apparatus for tissue ablation
US9113858B2 (en) High pressure and high temperature vapor catheters and systems
US8585645B2 (en) Treatment with high temperature vapor
CN102238920B (en) Method and apparatus for tissue ablation
EP2249734B1 (en) Determining patient-specific vapor treatment and delivery parameters
CN113015494A (en) Multi-stage steam ablation therapy method and steam generation and delivery system
US20130267939A1 (en) Methods and Apparatus for Ablating Lung Nodules with Vapor
JP2008523848A5 (en)
JP2022539457A (en) Devices and methods for treating ear, nose and throat disorders
US20150265331A1 (en) Devices for reducing lung volume and related methods of use
EP2094207B1 (en) High pressure and high temperature vapor catheters and systems
KR20230076822A (en) Systems and Devices for Treating Lung Tumors
KR20230097033A (en) Systems, devices and methods for treating lung tumors with a robotically delivered catheter

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REEP Request for entry into the european phase

Ref document number: 2005823129

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005823129

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/005937

Country of ref document: MX

Ref document number: 2007543222

Country of ref document: JP

Ref document number: 2587909

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020077013345

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580046606.8

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005823129

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0518437

Country of ref document: BR